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A B S T R A C T
Background
Asthma is a chronic respiratory condition characterised by airways inflammation, constriction of airway smooth muscle and structural
alteration of the airways that is at least partially reversible. Exacerbations of asthma can be life threatening and place a significant burden
on healthcare services. Various guidelines have been published to inform management personnel in the acute setting; several include
the use of a single bolus of intravenous magnesium sulfate (IV MgSO4) in cases that do not respond to first-line treatment. However,
the effectiveness of this approach remains unclear, particularly in less severe cases.
Objectives
To assess the safety and efficacy of IV MgSO4 in adults treated for acute asthma in the emergency department.
Search methods
We identified trials from the Cochrane Airways Review Group Specialised Register (CAGR) up to 2 May 2014. We also searched
www.ClinicalTrials.gov and reference lists of other reviews, and we contacted trial authors to ask for additional information.
Selection criteria
We included randomised controlled trials (RCTs) of adults treated in the emergency department (ED) for exacerbations of asthma if
they compared any dose of IV MgSO4 with placebo.
Data collection and analysis
All review authors screened titles and abstracts for inclusion, and at least two review authors independently extracted study characteristics,
risk of bias and numerical data. Disagreements were resolved by consensus, and we contacted trial investigators to obtain missing
information.
We analysed dichotomous data as odds ratios using study participants as the unit of analysis, and we analysed continuous data as mean
differences or standardised mean differences using fixed-effect models. We rated all outcomes using GRADE and presented results in
Summary of findings table 1.
We carried out subgroup analyses on the primary outcome for baseline severity of exacerbations and whether or not ipratropium
bromide was given as a co-medication. Unpublished data and studies at high risk of bias for blinding were removed from the main
analysis in sensitivity analyses.
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Main results
Fourteen studies met the inclusion criteria, randomly assigning 2313 people with acute asthma to the comparisons of interest in this
review.
Most studies were double-blinded trials comparing a single infusion of 1.2 g or 2 g IVMgSO4 over 15 to 30 minutes versus a matching
placebo. Eleven were conducted at a single centre, and three were multi-centre trials. Participants in almost all of the studies had already
been given at least oxygen, nebulised short-acting beta2-agonists and IV corticosteroids in the ED; in some studies, investigators also
administered ipratropium bromide. Ten studies included only adults, and four included both adults and children; these were included
because the mean age of participants was over 18 years.
Intravenous MgSO4 reduced hospital admissions compared with placebo (odds ratio (OR) 0.75, 95% confidence interval (CI) 0.60
to 0.92; I2 = 28%, P value 0.18; n = 972; high-quality evidence). In absolute terms, this odds ratio translates into a reduction of
seven hospital admissions for every 100 adults treated with IV MgSO4 (95% CI two to 13 fewer). The test for subgroup differences
revealed no statistical heterogeneity between the three severity subgroups (I2 = 0%, P value 0.73) or between the four studies that
administered nebulised ipratropium bromide as a co-medication and those that did not (I2 = 0%, P value 0.82). Sensitivity analyses in
which unpublished data and studies at high risk for blinding were removed from the primary analysis did not change conclusions.
Within the secondary outcomes, high- and moderate-quality evidence across three spirometric indices suggests some improvement in
lung function with IV MgSO4. No difference was found between IV MgSO4and placebo for most of the non-spirometric secondary
outcomes, all of which were rated as low or moderate quality (intensive care admissions, ED treatment duration, length of hospital
stay, readmission, respiration rate, systolic blood pressure).
Adverse events were inconsistently reported and were not meta-analysed. The most commonly cited adverse events in the IV MgSO4
groups were flushing, fatigue, nausea and headache and hypotension (low blood pressure).
Authors’ conclusions
This review provides evidence that a single infusion of 1.2 g or 2 g IV MgSO4 over 15 to 30 minutes reduces hospital admissions
and improves lung function in adults with acute asthma who have not responded sufficiently to oxygen, nebulised short-acting beta2-
agonists and IV corticosteroids. Differences in the ways the trials were conducted made it difficult for the review authors to assess
whether severity of the exacerbation or additional co-medications altered the treatment effect of IV MgSO4. Limited evidence was
found for other measures of benefit and safety.
Studies conducted in these populations should clearly define baseline severity parameters and systematically record adverse events.
Studies recruiting participants with exacerbations of varying severity should consider subgrouping results on the basis of accepted
severity classifications.
P L A I N L A N G U A G E S U M M A R Y
Do magnesium sulfate infusions reduce the need for hospital admission in adults with acute asthma?
Why is this question important?
Asthma is a long-term condition that causes coughing, wheezing, shortness of breath and chest tightness. When symptoms significantly
worsen, often referred to as an attack or ’exacerbation,’ this can be life threatening. Management of exacerbations in the emergency
department (ED) varies, and some guidelines recommend the use of intravenous magnesium sulfate (IVMgSO4) when other treatments
have not helped. However, it is unclear whether IV MgSO4 is effective, particularly in less severe cases, and we wanted to answer this
question.
How did we answer the question?
We looked for trials that compared IVMgSO4 versus placebo in adults attending the EDwith an asthma exacerbation. The most recent
searches were done on 2 May 2014. We were interested primarily in whether IV MgSO4 reduced the number of people needing to be
admitted to hospital, and we looked at several other measures as well, including time spent in the ED, lung function and symptom
scores.
What did we find?
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Fourteen studies met the inclusion criteria, involving a total of 2313 people. These studies varied in terms of how bad exacerbations
had to be for people to be included and in terms of what other treatments were provided before IV MgSO4was given, but almost all
trials gave participants at least oxygen, nebulised short-acting medications and steroid tablets or injection.
Overall, IV MgSO4 reduced the need for hospital admission compared with placebo (seven fewer per 100 treated; 95% confidence
interval two to 13 fewer). Not enough information was available to show whether the reduction in hospital admissions was associated
with severity of the asthma exacerbation, or whether it made a difference what other treatments were given. Evidence suggests that IV
MgSO4 improved some lung function parameters, but for other measures such as heart rate, variation among study findings reduced
our confidence in the results. We did not find a difference between IV MgSO4 and placebo in most other measures (including time
spent in the ED, respiratory rate and blood pressure), and adverse events generally were poorly reported.
Conclusion
This review showed that IV MgSO4 reduces hospital admissions and improves lung function in adults with exacerbations of asthma
when other first-line medications have not relieved the acute symptoms (i.e. oxygen, inhaled short-acting medications and IV steroids).
Evidence for other measures of benefit and safety was limited.
Researchers should clearly define the severity of the asthma condition among people in their studies while carefully recording adverse
events.
This plain language summary is current as of May 2014.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
IV MgSO4 for treating adults with acute asthma in the ED
Patient or population: adults with acute asthma
Settings: emergency department
Intervention: IV MgSO4
Comparions: placebo
Both intervention and placebo groups received oxygen, short-acting beta2-agonists and oral or intravenous steroids before the infusion
Measurements were taken between 60 and 240 minutes after the start of the infusion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control IV MgSO4
Hospital admissions 569 per 1000 498 per 1000
(442 to 549)
OR 0.75
(0.60 to 0.92)
1769
(11 studies)
⊕⊕⊕⊕
high1,2
Intensive care unit (ICU) ad-
missions
14 per 1000 28 per 1000
(10 to 77)
OR 2.03
(0.7 to 5.89)
752
(1 study)
⊕⊕©©
low3,4
Length of hospital stay (days) Mean length of hospital stay in
the control groups was
2.73 days5
Mean length of hospital stay in
the intervention groups was
0.03 days lower
(0.33 lower to 0.27 higher)
- 949
(3 studies)
⊕⊕©©
low6,7,8
ED treatment duration (min-
utes)
Mean duration in the placebo
group was
228 minutes
Mean ED treatment duration in
the intervention groups was
4 minutes lower
(37.02 lower to 29.02 higher)
- 96
(1 study)
⊕⊕©©
low9,10,11
FEV1 (% predicted) Mean FEV1 in the placebo
group was
50% predicted
Mean FEV1 (% predicted) in
the intervention groups was
4.41 higher
(1.75 to 7.06 higher)
- 523
(4 studies)
⊕⊕⊕⊕
high12,13,14
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PEF (L/min) Mean PEF in the placebo group
was
239 L/min
Mean PEF in the intervention
groups was
17.4 L/min higher
(8.64 to 26.17 higher)
- 1460
(8 studies)
⊕⊕⊕©
moderate15,16,17
Respiratory rate (breaths/
min)
Mean respiration rate in the
placebo group was
20.7 respirations/min
Mean respiratory rate in the
intervention groups was
0.28 breaths/min lower
(0.77 lower to 0.2 higher)
- 1195
(4 studies)
⊕⊕⊕©
moderate18,19,20
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; ED: Emergency department; FEV1 : Forced expiratory volume in 1 second; ICU: Intensive care unit; IV: Intravenous; MgSO4: Magnesium sulfate; OR: Odds ratio; PEF:
Peak expiratory flow.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1One study (Green 1992) introduced risk of bias, but the rest of the studies were generally well conducted.
2I2 = 28%; P value 0.18; not statistically significant.
3Confidence interval includes potential benefit and harm. Very few events and only 1 study (-2 for imprecision).
4Only 1 study (Goodacre 2013) reported this outcome, but no other studies set out to measure it at the outset.
5Weighted by sample size.
6Two of the 3 studies were at high risk of bias for blinding, and there were some issues with selection bias.
7I2 = 58%; P value 0.07, suggesting statistically significant heterogeneity.
8Although only 3 studies reported this outcome, it was not named as an outcome in other studies.
9Only 1 study (Green 1992), which was assessed as having high risk of bias for several domains.
10Only 1 study (Green 1992), which had wide confidence intervals (-37.02 to 29.02).
11Only 1 study reported ED treatment duration, but it was not named as an outcome in other studies.
12Only 1 study (Bilaceroglu 2001) had the potential for risk of bias, but all other studies were low risk and included large numbers of
participants.
13No significant heterogeneity was noted (I2 = 14%; P value 0.33).
14Moderately wide confidence interval (1.75 to 7.06), but after discussion, review authors decided that no downgrade was required.
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15Two studies (Green 1992; Matusiewicz 1994) had ’unclear’ and ’high’ risk of bias, respectively. However, the remaining 6 studies were
of low risk and contributed most of the participant numbers.
16Some heterogeneity between the studies, which was statistically significant (I² = 50%; P value 0.05). However, when random effects
were applied, conclusions were not changed.
17Wide confidence intervals (8.64 to 26.17), but does not cross zero.
18Very little heterogeneity observed between the studies (I² = 1%), which was not significant (P value 0.39).
19Confidence interval (-0.77 to 0.20) includes significant benefit and potential harm (i.e. crosses the line of no effect).
20Only 4 studies reported respiratory rate, but it was not named as an outcome in other studies.
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B A C K G R O U N D
Description of the condition
Asthma is a chronic respiratory condition characterised by airway
inflammation, constriction of airway smooth muscle and struc-
tural alteration of the airways that is at least partially reversible.
Common symptoms include cough, wheezing, difficulty breath-
ing, reduced exercise tolerance and chest tightness. Common trig-
gers include allergens, pollutants and viral infections, although
endogenous factors have also been identified. The World Health
Organization (WHO) recognises the global burden of asthma and
estimates a worldwide prevalence of 300 million people of all
ages, with 250,000 dying each year. Epidemiological data suggest
that prevalence is greatest in the developed world, with prevalence
amongst adults at 8.2% in the USA (CDC) and 9% to 10% in
the UK (DOH 2012).
Asthma can present with varying degrees of severity, and in the
most severe cases, it can cause daily chronic symptoms and frequent
exacerbations (defined as acute worsening of asthma symptoms).
Overarching principles of treatment focus on controlling daily
symptoms and preventing exacerbations through good education
and appropriate use of inhalers. Short-acting bronchodilators are
given to relieve bronchospasm, and corticosteroids for the underly-
ing inflammation; both are usually delivered via inhalers. Depend-
ing on the persistence of symptoms, inhalers can be taken regularly
(maintenance therapy) or on an as-needed basis (reliever therapy)
(BTS/SIGN 2012; GINA 2011). Treatment guidelines recom-
mend preventative management in the community and prompt
interventions during exacerbations to reduce mortality and other
negative outcomes (such as intubation and hospital admissions).
Description of the intervention
In severe exacerbations of asthma, which can be life threaten-
ing, most guidelines recommend the use of oxygen, nebulised or
intravenous beta2-agonists, nebulised antimuscarinics and intra-
venous or oral corticosteroids as first-line treatment (BTS/SIGN
2012; GINA 2011; NACA 2006; NAEPP 2007). Beta2-agonists
are recognised as most effective in relieving bronchospasm (Teoh
2012); however, anticholinergic inhalers have also been shown to
be effective in the treatment of acute asthma (Griffiths 2013).
When patients show poor response to these, or when they present
with a severe or life-threatening exacerbation, a single dose of in-
travenous (IV) or nebulised magnesium sulfate (MgSO4) can be
considered. Nebulised MgSO4 is the subject of a separate review
(Powell 2012). The recommended dosage of IVMgSO4 in theUK
is 1.2 g to 2 g, delivered by infusion over 20 minutes (BTS/SIGN
2012), but guidelines differ regarding how and when IV MgSO4
should be administered (Table 1),
National guidelines also vary with respect to definitions of asthma
severity and use of additional interventions. Table 1 offers a sum-
mary of treatment strategies recommended by some of these guide-
lines for the management of acute asthma.
How the intervention might work
Magnesium is an important intracellular and extracellular cation
that plays a key role in intracellular enzymatic reactions. Its mech-
anism of action in the context of an exacerbation of asthma is not
fully understood, but several theories have been proposed (Rowe
2013). It is believed to play a role in bronchial smooth muscle
relaxation via its ability to prevent calcium ion movement into
smooth muscle cells by blocking the voltage-dependent calcium
channels (Gourgoulianis 2001; Spivey 1990). Furthermore, some
evidence suggests that it may reduce the neutrophilic burst seen
with the inflammatory response (Cairns 1996), and that it may be
involved in acetylcholine release from cholinergic nerve terminals
and histamine release from mast cells (Dominguez 1998). The
combination of these properties contributes to relief of airflow ob-
struction and provides the theoretical basis for the effectiveness of
magnesium.
Why it is important to do this review
Acute asthma presentations represent a significant burden on
emergency departments (EDs) and carry a substantial mortality
risk, with 1143 deaths from asthma reported in the UK in 2010
(Asthma UK) and an estimated mortality rate of 1.1 deaths per
100,000 in the USA (CDC). In the UK, it is thought that “75%
of hospital admissions for asthma are avoidable and as many as
90% of the deaths from asthma are preventable” (Asthma UK).
The financial burden is also significant, with a cost to theNational
Health Service (NHS) of £1 billion a year, 80% of which is spent
on the 20% of people with the most severe disease (DOH 2012).
Current guidelines advocate the use of IV MgSO4 in the treat-
ment of acute severe asthma, but evidence in the literature remains
inconclusive (Rowe 2009). New evidence from randomised con-
trolled trials published since the last version of this review may
alter the conclusions.
O B J E C T I V E S
To assess the safety and efficacy of IV MgSO4 in adults treated for
acute asthma in the emergency department.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of any follow-
up duration reported as full text, those published as abstract only
and unpublished data.
Types of participants
We included studies of adults (defined as over 18 years of age)
treated in the ED for acute asthma. If studies recruited both adults
and children, we contacted the study authors to try to obtain
separate data from adults.
Types of interventions
We included trials comparing any dose of IV MgSO4 versus
placebo. People with acute asthma often require multiple medica-
tions; therefore we included studies that allowed other treatments
(for maintenance, for exacerbation itself or for other co-morbidi-
ties), provided they were not part of the randomly assigned treat-
ment.
Types of outcome measures
Primary outcomes
• Hospital admissions.
Secondary outcomes
• ED treatment duration.
• Intensive care unit admissions.
• Vital signs (heart rate, respiratory rate, blood pressure,
oxygen saturation).
• Spirometry (peak expiratory flow (PEF), forced expiratory
volume within one second (FEV1)).
• Validated symptom scores.
• Adverse events.
Reporting in the trial of one or more of the outcomes listed here
was not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Review Group
Specialised Register (CAGR), which is maintained by the Trials
Search Co-ordinator for the Group. The Register contains trial
reports identified through systematic searches of bibliographic
databases including the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED
and PsycINFO, and by handsearching of respiratory journals and
meeting abstracts (see Appendix 1 for further details).We searched
all records in the CAGR using the search strategy described in
Appendix 2.
We also
conducted a search of ClinicalTrials.gov (www.ClinicalTrials.gov)
and theWHO trials portal (www.who.int/ictrp/en/). We searched
all databases from their inception to the present, and we imposed
no restriction on language of publication.
Searching other resources
Wechecked reference lists of all relevant primary studies and review
articles for additional references. We also searched for errata or
retractions from included studies published in full text on PubMed
(www.ncbi.nlm.nih.gov/pubmed) and reported within the review
the date this was done.
Data collection and analysis
Selection of studies
Three review authors (KK, LK, CM) independently screened ti-
tles and abstracts for inclusion of all citations identified by the
search and coded them as ’retrieve’ (eligible or potentially eligible/
unclear) or ’do not retrieve.’ We retrieved the full-text study re-
ports/publications, and the review authors independently screened
the full-text documents and identified studies for inclusion. We
identified and recorded reasons for exclusion of ineligible studies.
We resolved disagreements through discussion, or, if required, we
consulted a fourth person. We identified and excluded duplicates
and collated multiple reports of the same study, so that each study
rather than each report was the unit of interest in the review. We
recorded the selection process in sufficient detail to complete a
PRISMA flow diagram and a Characteristics of excluded studies
table.
Data extraction and management
To record study characteristics and outcome data, we used a data
collection form that had been piloted on at least one study in the
review. All review authors (KK, LK, CM) extracted study char-
acteristics from included studies, and all review authors indepen-
dently extracted outcome data. We extracted the following study
characteristics.
• Methods: study design, duration of observation and follow-
up, details of any ’run-in’ period, number of study centres and
locations, withdrawals, dates of study.
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• Participants: N, mean age, age range, gender, asthma
severity*, diagnostic criteria, co-morbidities, co-medications,
baseline lung function, inclusion and exclusion criteria.
• Interventions: intervention, dose, comparison, concomitant
and failed treatments, excluded medications.
• Outcomes: primary and secondary outcomes specified and
collected, time points reported.
• Notes: funding for trial, notable conflicts of interest of trial
authors.
We noted in the Characteristics of included studies table if out-
come data were not reported in a usable way. We resolved dis-
agreements by reaching consensus or by involving a fourth per-
son. One review author transferred data into the Review Manager
(RevMan) (version 5.2) file. We double-checked that data were
entered correctly by comparing data presented in the systematic
review versus data provided in the study reports. A second review
author (LK or CM) spot-checked study characteristics for accu-
racy against the trial report.
Assessment of risk of bias in included studies
All review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), resolving dis-
agreements by discussion. We assessed the risk of bias according
to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justification
for our judgement in the Risk of bias in included studies table.
We summarised risk of bias judgements across different studies
for each of the domains listed. We considered blinding separately
for different key outcomes when necessary (e.g. for unblinded
outcome assessment, risk of bias for hospital admission may be
very different than for a patient-reported scale).When information
on risk of bias was related to unpublished data or correspondence
with a trial author, we noted this in the Risk of bias in included
studies table.
When considering treatment effects, we took into account the risk
of bias for all studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol and
reported deviations from it in the Differences between protocol
and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios (ORs) and contin-
uous data as mean differences (MDs) or standardised mean dif-
ferences (SMDs) with 95% confidence intervals (CIs). If studies
reported several validated symptom measures, or if different scales
were reported across studies, we analysed the data as SMDs in one
analysis to reduce measurement error and to increase precision.
We entered data presented as a scale with a consistent direction of
effect. We narratively described skewed data reported as medians
and interquartile ranges.
We undertook meta-analyses only when this was meaningful (i.e.
when treatments, participants and the underlying clinical question
were similar enough for pooling to make sense).
When multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. When two relevant comparisons
from a single study were combined in the same meta-analysis, we
halved the control group to avoid double-counting.
Unit of analysis issues
For dichotomous outcomes, we used participants rather than
events as the unit of analysis (i.e. number of adults admitted to
hospital rather than number of admissions per adult).
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study was identified as abstract only).
When this was not possible, and when missing data were thought
to introduce serious bias, we conducted a sensitivity analysis to
explore the impact of including such studies in the overall assess-
ment of results.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. When substantial heterogeneity was identified,
we explored possible causes by conducting prespecified subgroup
analyses.
Assessment of reporting biases
We created and examined a funnel plot to explore possible small-
study and publication biases. We considered the impact of unpub-
lished trials in the GRADE ratings for each outcome.
Data synthesis
We used a fixed-effect model and performed a sensitivity analysis
with random effects when significant heterogeneity was observed
(I² > 30%).
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Summary of findings table
We created Summary of findings for the main comparison for
seven of the prespecified outcomes. We used the five GRADE
considerations (study limitations, consistency of effect, impre-
cision, indirectness and publication bias) to assess the quality
of a body of evidence as it relates to the studies that con-
tributed data tometa-analyses for the prespecified outcomes (http:
//www.gradeworkinggroup.org/). We applied methods and rec-
ommendations described in Section 8.5 and Chapter 12 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011) using GRADEpro software. We justified all decisions to
downgrade or upgrade the quality of studies by using footnotes,
and we made comments to aid readers’ understanding of the re-
view when necessary.
Subgroup analysis and investigation of heterogeneity
We carried out the following subgroup analyses for the primary
outcome, using the formal test for subgroup differences in Review
Manager (version 5.2) (Review Manager (RevMan)).
• Baseline severity (moderate, severe and life-threatening
exacerbations*).
• Mean age (≤ and > 65 years).
• Co-medications (with or without ipratropium bromide**).
*Since there is no single accepted metric for assessment of asthma
severity, we extracted baseline data relevant to the severity criteria,
as stated in the British Thoracic Society (BTS) guidelines (BTS/
SIGN 2012), that is,
• Clinical features (e.g. ability to complete sentences,
respiratory effort, conscious level, signs of exhaustion);
• Previous intensive care unit admissions;
• Pulse;
• Blood pressure;
• Respiratory rate;
• Pulse oximetry;
• Pulsed expiratory flow (PEF); and
• Arterial blood gas.
Exacerbations of the study populations were labelled as moderate,
severe or life threatening on the basis of available data, as judged by
an independent assessor who was not involved in the review pro-
cess and had no other details or results of the trials. Consistent with
British Thoracic Society (BTS)/Scottish IntercollegiateGuidelines
Network (SIGN) criteria (BTS/SIGN 2012), for which the per-
centage predicted PEF was available, mean values less than 33%
were judged to be life threatening, 33% to 50% severe and over
50% moderate. When this measure was not available, or when
the value was close to a cutoff, other criteria were consulted, and
the value was then standardised across trials using studies report-
ing several indices. The decision to perform a subgroup analysis
by severity was informed by conclusions drawn in the previous
Cochrane review (Rowe 2009) that the intervention may be more
effective in cases of severe or life-threatening asthma.
**For co-medications, we grouped studies bywhether investigators
gave ipratropium bromide in addition to other treatments (i.e.
short-acting beta2-agonists (SABAs) via a nebuliser or spacer, oral
or intravenous corticosteroids). Ipratropium bromide is included
in most guidelines, but it is unclear whether this treatment is
adopted in all EDs. Griffiths 2013 has demonstrated that it is an
effective adjunct to SABAs in children with asthma exacerbation
in the acute setting.
Sensitivity analysis
We plan to carry out the following sensitivity analyses.
• Studies at high risk of bias for blinding.
• Unpublished data.
Reaching conclusions
We have based our conclusions only on findings from the quan-
titative or narrative synthesis of included studies for this review.
We have avoided making recommendations for practice, and our
implications for research suggest priorities for future research and
outline remaining uncertainties in this area.
R E S U L T S
Description of studies
Full details of the conduct and characteristics of each included
study can be found in Characteristics of included studies, and rea-
sons for exclusion when full texts had to be viewed are given in
Characteristics of excluded studies.
Results of the search
119 references were identified by electronic searches, and 27 addi-
tional records were identified by a search of clinicaltrials.gov. Most
were excluded upon screening of titles and abstracts (n = 117).
Full texts were consulted for the remaining 29 references, and 10
were excluded at this stage, primarily because the study was not
conducted in an emergency setting (n = 7). Other reasons for ex-
clusion at this stage were ’study population did not have asthma’
(n = 2) and ’no placebo comparison’ (n = 1). Several unsuccessful
efforts were made to find a trial publication for one additional
study (Abd El Kader 1997), which is awaiting classification. The
remaining 18 citations related to 14 studies, which were included
in this review. Trial flow is presented in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Fourteen studies met the inclusion criteria, randomly assigning
2313 people with acute asthma to the comparisons of interest in
this review. Goodacre 2013 contributed the largest sample size to
the analyses, with 1109 participants randomly assigned to the two
intervention groups; in contrast, Del Castillo Rueda 1991 had
the smallest sample size, with 16 participants randomly assigned
to the intervention groups. Mean sample size across the included
studies was 165. Summary characteristics of the included trials are
presented in Table 2, and full details of each included study are
given in Characteristics of included studies.
Design and duration
Most of the studies included in this review were randomised,
double-blinded, placebo-controlled trials. Of those that were not,
two were randomised, single-blinded, placebo-controlled trials
(Bilaceroglu 2001; Singh 2008), one was unblinded with the con-
trol group receiving no placebo (Green 1992) and for two trials,
the study design was unclear from the information provided (Del
Castillo Rueda 1991; Matusiewicz 1994). For these two studies,
the former commented on randomisation but not blinding, and
the latter commented on neither randomisation nor blinding, al-
though both studies appeared to include treatment and control
groups.
The duration of the studies ranged from 45 minutes (Skobeloff
1989) to 260 minutes (Tiffany 1993). Most trials reported out-
come data at the end of study treatment periods, but further
follow-up provided in five studies ranged from six hours to one
month (Bijani 2001; Bilaceroglu 2001; Bloch 1995; Goodacre
2013; Silverman 2002). Most trials were conducted at a single
centre, occurring within one ED, except for Bloch 1995, which
was done across two EDs in the USA; Goodacre 2013, which took
place across 34 EDs in the UK and Silverman 2002, which was
completed across eight EDs in the USA.
Participant inclusion and exclusion criteria
All studies included participants with an exacerbation of asthma.
However differences between studies included the measures used
to define an exacerbation, with some using PEF and others using
FEV1, as well as the time at which these measurements were taken
(e.g. on arrival, after initial treatment).
PEF was used in seven studies (Bijani 2001; Bilaceroglu 2001;
Bradshaw 2007; Goodacre 2013;Matusiewicz 1994; Porter 2001;
Skobeloff 1989). Two studies (Bijani 2001; Skobeloff 1989) used
PEF< 200L/min, Porter 2001 used PEF< 100 or < 25%predicted
and Matusiewicz 1994 specified PEF < 250 L/min or < 50% pre-
dicted as the cutoff to indicate an exacerbation. Both Bilaceroglu
2001 and Goodacre 2013 specified PEF < 50% predicted as a
cutoff. FEV1 was used as a criterion for inclusion in four stud-
ies (Bilaceroglu 2001; Bloch 1995; Silverman 2002; Singh 2008),
with the cutoff being FEV1 < 75% predicted (Bilaceroglu 2001;
Bloch 1995) or FEV1 < 30% (Silverman 2002; Skobeloff 1989).
Boonyavorakul 2000 used a severity score > 4 (Fischl Index, which
is a composite of vital signs, PEF and clinical features). Three stud-
ies (Del Castillo Rueda 1991; Green 1992; Tiffany 1993) did not
define the criteria used for an exacerbation.
Three studies did not define any exclusion criteria (Bijani 2001;
Del Castillo Rueda 1991; Matusiewicz 1994). For the remaining
studies (n = 11), exclusion criteria were quite consistent and in-
cluded diabetes mellitus, congestive cardiac disease, hypertension,
chronic renal failure, temperature > 38 ºC, pneumonia, pregnancy,
participants requiring ventilation and those who did not provide
consent.
Baseline characteristics of participants
The most common age range used across studies was 18 to 60
years (Silverman 2002; Singh 2008; Tiffany 1993). Bloch 1995
and Green 1992 used a range of 18 to 65 years, Porter 2001 18 to
55 years and Skobeloff 1989 18 to 60 years. Two studies (Bradshaw
2007; Goodacre 2013) included participants 16 years of age and
older, whilst Boonyavorakul 2000 included participants aged 15
to 65 years. Two studies included children and reported age ranges
of 12 to 85 years (Bijani 2001) and six to 65 years (Bilaceroglu
2001). From the studies for which we have only the abstract, Del
Castillo Rueda 1991 did not specify the age of participants, and
Matusiewicz 1994 described participants as ’adults.’
Most of the studies were well matched between control and inter-
vention with respect to sex (other than Porter 2001, in which the
IV MgSO4arm consisted of 50% men compared with 25% in the
placebo arm).
Only four studies reported ethnicity data (Bilaceroglu 2001;
Goodacre 2013; Green 1992; Silverman 2002). The percent-
age classified as ’white’ ranged from 59% to 100% in three of
these (Bilaceroglu 2001; Goodacre 2013; Green 1992), whereas
Silverman 2002 had a greater preponderance of black and His-
panic participants, with only 11% to 14% of participants classi-
fied as ’white.’
Five studies distinguished smokers (Bilaceroglu 2001; Bloch 1995;
Goodacre 2013; Silverman 2002; Singh 2008), and in all cases
the placebo and intervention arms were well matched. The per-
centage of current smokers within these studies ranged from 7%
to 10% in Singh 2008, to 30% to 35% in Goodacre 2013 and
Silverman 2002. The remainder of the studies (Bilaceroglu 2001;
Bloch 1995) combined current smokers and ex-smokers, and their
proportions ranged from 29% to 50%.
12Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Three studies further stratified participants by severity of asthma
using American (Bilaceroglu 2001; Bloch 1995) and British
(Bradshaw 2007) Thoracic Society Guidelines.
As stated in the protocol, we categorised study populations on the
basis of average severity to conduct a subgroup analysis. Judge-
ments of severity were based on baseline severity characteristics
presented in the trials, which are summarised in Table 3. The justi-
fication for each judgement is given in each study’s characteristics
table.
Characteristics of the interventions
IV MgSO4
In nine studies a dose of 2 g IV was used, usually in 50 to 100 mL
(250 mL in Singh 2008) of 0.9% normal saline or 5% dextrose
solution, and was infused over periods ranging from 15 to 30
minutes.
Bradshaw 2007, Del Castillo Rueda 1991, Matusiewicz 1994 and
Skobeloff 1989 used a dose of 1.2 g IV MgSO4 in solutions akin
to those mentioned above. Bijani 2001 used doses calculated by
weight of 25 mg/kg; this reflects the broader age range of the
participants.
Placebo group
All studies had a placebo arm except Green 1992, in which no
placebo was administered to the control group. In all other cases,
the same solution that was used to infuse IV MgSO4 to the treat-
ment group was used as the control solution, in equal volume
and over the same time period. Boonyavorakul 2000 added 2 mL
sterile water to the control solution, and Silverman 2002 does not
comment on the specific solution used for control but describes it
as ’like appearing solution’ of equal volume.
Co-medications
A number of other drugs commonly used in acute asthma were
co-administered, and there was a degree of variation in the way
this was done. In all trials participants received nebulised SABA
(salbutamol and, in one case, metaproterenol sulfate), and most
also described the use of oxygen (n = 10) and IV corticosteroids
(n = 10) before IV MgSO4 was given.
Goodacre 2013 administered oral prednisolone rather than IV
corticosteroids, and the form of corticosteroid administered was
unclear in Bijani 2001, Del Castillo Rueda 1991 and Bilaceroglu
2001. In the latter, the decision to administer was based on the
severity category to which the participant had been assigned.
Use of oxygen was described in 10 studies, although some study
authors commented that this was the case only if clinically indi-
cated (Bilaceroglu 2001; Boonyavorakul 2000). Some authors did
not describe the use of oxygen, although they may not have con-
sidered this to be a drug treatment requiring mention in the treat-
ment protocol (Bloch 1995; Del Castillo Rueda 1991; Skobeloff
1989; Tiffany 1993).
Three studies administered aminophylline or theophylline (Bijani
2001; Skobeloff 1989; Tiffany 1993), and in Skobeloff 1989, this
was guided by serum theophylline levels.
Nebulised ipratropium bromide was administered in four stud-
ies (Bradshaw 2007; Goodacre 2013; Matusiewicz 1994; Singh
2008). Goodacre 2013 andGreen 1992 commented that other in-
terventions were permitted at the discretion of the treating physi-
cian, although they did not specify which ones were permitted.
Outcomes and analysis structure
Most studies reported the number of participants who required
hospitalisation after treatment (n = 11), but secondary outcomes
were inconsistently reported. Three studies reported length of hos-
pital stay for those hospitalised, and only one study at high risk of
bias reported the duration of ED treatment (Green 1992). Read-
mission was reported in Bloch 1995 and Goodacre 2013 after a
week and a month, respectively.
Lung function was reported in most of the studies, although this
was done in different ways (primarily percentage predicted FEV1
and PEF, and PEF in litres per minute). Absolute values or changes
in FEV1 (L) were not consistently reported. Bloch 1995 did not
report standard deviation for FEV1, but the study was included
on the basis of variance derived from the P value reported in the
paper. This resulted in an unusually large standard deviation but
did not significantly change the final results.
In the PEF analysis, we combined three studies reporting mean
change from baseline (Bijani 2001; Skobeloff 1989; Tiffany 1993)
with five reporting absolute endpoint scores (Goodacre 2013;
Green 1992; Matusiewicz 1994; Porter 2001; Silverman 2002).
Four studies reported heart rate, respiratory rate and systolic blood
pressure (Bloch 1995; Goodacre 2013; Silverman 2002; Singh
2008). Bijani 2001 reported respiratory rate, but the data could
not be included because no measure of variance was provided.
Goodacre 2013 reported oxygen saturation for participants on and
off oxygen separately, but because no other studies reported data,
we did not perform a meta-analysis. Partial pressure was reported
in one study (Bilaceroglu 2001), but again this was not formally
analysed. These results are summarised narratively.
Validated symptom scales generally were not reported in the stud-
ies, but four studies reported scores on the Borg Dyspnoea Scale
(Bloch 1995; Porter 2001; Silverman 2002; Singh 2008). One
additional study (Goodacre 2013) measured breathlessness using
a visual analogue scale (VAS), which we chose not to analyse, as
it was not validated. Boonyavorakul 2000 used the Fischl Index,
which is a composite of vital signs, PEF and clinical features. As
individual measures were not available, the data were not analysed.
A large degree of disparity was noted in the reporting of adverse
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events; this precluded pooling of data in the meta-analysis. Five
studies reported no information on adverse events (Bijani 2001;
Del Castillo Rueda 1991; Matusiewicz 1994; Silverman 2002;
Tiffany 1993), although Silverman 2002 noted that no major ad-
verse events were reported. Boonyavorakul 2000 and Green 1992
described minor adverse events such as flushing and fatigue, but
these were not quantified. Other studies quantified adverse events
for the duration of the treatment period, which ranged from 60 to
240 minutes. As such, we summarised information across studies
narratively in the results.
Subgroup and sensitivity analyses
We conducted subgroup analyses on the primary outcome (hospi-
tal admissions) for baseline severity and co-medications. For sever-
ity, 15 groups were identified across the 11 studies reporting the
outcome: two moderate, six severe and seven life threatening.
We performed the analysis based onwhether ipratropiumbromide
was administered as described in the protocol. Bradshaw 2007,
Goodacre 2013, Matusiewicz 1994 and Singh 2008 were the only
studies in which ipratropium bromide was given; three of these
are UK studies. However, as information about co-medications
was inconsistently reported (summarised above and in Table 2),
and it was often unclear when infusions or nebulisers were given,
we were conservative in interpretation and have summarised the
limitations of the analysis in the discussion. We could not carry
out a subgroup analysis based on mean age (≤ and > 65 years), as
no trials solely recruited older adults.
We also conducted two sensitivity analyses excluding trials at high
risk of bias for blinding and those that contributed only unpub-
lished data. Bilaceroglu 2001, Green 1992 and Matusiewicz 1994
were removed from the prior, and only Matusiewicz 1994 from
the latter. No full paper was available for Del Castillo Rueda 1991,
but this study did not report hospital admissions, and although
only an abstract was available in English for Bilaceroglu 2001, the
full paper had been published in Turkish, from which we were
able to obtain further information. None of the studies provided
additional unpublished data for the primary outcome.
We added a post-hoc sensitivity analysis using change from base-
line instead of endpoint means from Goodacre 2013, as baseline
imbalances were noted in this study.
Excluded studies
Studies that took place outside of an acute setting were excluded,
as were those concerned with the effects of nebulised magnesium
sulfate (the subject of another review (Powell 2012)).
We excluded trials that were exclusively concerned with children,
defined as those younger than 18 years of age. These studies will be
dealt with in a separate Cochrane review (Griffiths 2014). We in-
cluded studies in which participants were both older and younger
than 18. Bradshaw 2007 and Goodacre 2013 included partici-
pants 16 years of age and older, and we believe that these data
are applicable to adults, as we would not expect significant phys-
iological differences between the ages of 16 and 18. Bijani 2001,
Boonyavorakul 2000 and Bilaceroglu 2001 included participants
12 to 85 years and 15 to 65 years of age, respectively; we endeav-
oured to obtain data for adults only but were ultimately unsuc-
cessful. Age ranges were unclear in three studies, although the im-
plication was that participants were adults (Bilaceroglu 2001; Del
Castillo Rueda 1991; Matusiewicz 1994).
Risk of bias in included studies
For details of the risk of bias rating for each study and the reasons
for each rating, see Characteristics of included studies. A sum-
mary of risk of bias judgements by study and domain (alloca-
tion generation, allocation concealment, blinding and incomplete
data) can be found in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We assessed six studies to be at low risk of bias for random sequence
generation and seven for allocation concealment. Both Bloch 1995
and Bradshaw 2007 used random number generation by phar-
macy,with blinding of physicians to the allocation.Goodacre 2013
used telephone- or Internet-generated randomisation sequencing,
whilst Porter 2001 used a random number generator producing
a code, and in both studies, numbered treatment packs were pre-
pared in pharmacy before they were used by physicians. Silverman
2002 used 1:1 randomisation tables, and the pharmacy prepared
vials of placebo or IV MgSO4 with identical appearances and la-
belled with study IDs. Singh 2008 used 1:1 randomisation tables,
and study numbers were concealed in envelopes until allocation
was completed.
Skobeloff 1989 did not provide sufficient details of random se-
quence allocation to warrant a low risk bias judgement but ade-
quately described allocation concealment.
Two studies (Boonyavorakul 2000; Tiffany 1993) detailed ad-
equate randomisation processes (computer-generated lists); in
Tiffany 1993, this was managed by pharmacy, but no information
about allocation concealment was provided, and hence this study
was assessed to be at unclear risk in this domain.
Bilaceroglu 2001, Del Castillo Rueda 1991 and Bijani 2001 com-
mented on randomisation, although no further details were pro-
vided and no comment on allocation concealment was made;
hence these studies were assessed as unclear in both areas. The
same assessment was made with Matusiewicz 1994, for which no
information about randomisation or allocation concealment was
provided.
We considered Green 1992 to be at high risk of bias in these
domains, as participants were allocated to control or treatment
group according to the day of presentation to the department.
Blinding
In the domains of both performance and detection bias, we con-
sideredmost (n = 8) of the included studies to be at low risk of bias
(Bloch 1995; Boonyavorakul 2000; Bradshaw 2007; Goodacre
2013; Porter 2001; Silverman 2002; Skobeloff 1989; Tiffany
1993). These were described as double-blinded placebo-controlled
trials, and investigators provided adequate detail about who was
blinded and commented that their primary outcomes were non-
subjective assessor-rated outcomes.
Singh 2008 described this study as single-blinded; however
through correspondence with the study author, we were able to
ascertain that participants and assessors of spirometric and clin-
ical outcomes were blinded, as was the chief resident who made
the decision about admission. The individual administering the
medication was unblinded; therefore we rated performance bias
as ’unclear’ and detection bias as ’low risk.’
We believe that although Bijani 2001 performed a double-blinded
study with decoding done at completion of the study, limited
detail was provided about who the blinded parties were, and we
considered this to be unclear.
We have no information for these domains from Del Castillo
Rueda 1991 and Matusiewicz 1994 and have graded them as also
having unclear risk of bias.
We assessed that both Bilaceroglu 2001 and Green 1992 are at
high risk of bias in these domains. The former study was single-
blinded, and further correspondence with the study author con-
firmed that only participants were blinded to treatment, allowing
for bias in assessment of outcome measures. In Green 1992, the
physicians were unblinded to randomisation, and although nei-
ther participants nor respiratory therapists carrying out PEF mea-
sures were aware that a study was being conducted, they may have
been aware of the treatment received.
Incomplete outcome data
We considered that in half of the included studies (n = 7), the risk
of attrition bias was low, and in the other half, the risk was unclear.
In studies for which we considered the risk to be low (Bilaceroglu
2001; Bloch 1995; Boonyavorakul 2000; Bradshaw 2007;
Goodacre 2013; Singh 2008; Skobeloff 1989), withdrawal rates
were clearly documented and numbers were low, with similar rates
reported in placebo and control groups.
In four studies (Bijani 2001; Del Castillo Rueda 1991;
Matusiewicz 1994; Tiffany 1993), no information was provided
about withdrawal rates, hence the reason for considering the risk
to be unclear.
In Green 1992, 97 of 217 participants were excluded from anal-
ysis, with 80 participants repeat attenders (no comment on the
groups to which they had been randomly assigned) and the med-
ical records of 17 participants misplaced. No comment was made
about whether there was intention to treat any of the participants
who withdrew, although at the point of analysis, numbers in all
groups were similar.
Porter 2001 reports that where repeat attendance to the depart-
ment was documented, data from only the first presentation were
used, but no further commentary was made about withdrawals.
Silverman 2002 provides a very detailed report of participants with
protocol violations who were retained in the intention-to-treat
data set and gives reasons for these inclusions. However, attrition
rates were quite high and were not provided for each arm. As such
it was unclear whether attrition was balanced between groups, and
the study was rated as ’unclear.’
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Selective reporting
We considered that only five studies demonstrated low risk of bias
in reporting of outcome data: Bijani 2001; Bloch 1995; Goodacre
2013; Silverman 2002; and Singh 2008. Although Bijani 2001 did
not report on arterial blood gas (ABG) results aswas planned, other
data were well reported, and we believe that the ABGmeasure was
not critical to the study. Both Goodacre 2013 and Singh 2008
provided further raw data when directly contacted by the review
authors, and this completed the outcomes planned for assessment.
The published report of Bloch 1995 provided data at only one of
the prespecified time points and FEV1 was provided graphically,
but the study author provided additional data to the review authors
upon request.
We considered the following studies to be unclear for risk of re-
porting bias: Bilaceroglu 2001; Del Castillo Rueda 1991; Green
1992; Matusiewicz 1994; and Porter 2001. We have only the ab-
stract for both Del Castillo Rueda 1991 and Matusiewicz 1994;
The former provided no outcome data, just a written description
of investigator conclusions, and the latter provided outcomes at
only one of the recorded time points. Bilaceroglu 2001 did pro-
vide further raw data to the review authors on request, but this
still did not include all time points laid out in the methodology.
Green 1992 provided outcome data, but the methodology did not
indicate the primary outcome measures selected when the study
was designed. Porter 2001 provided all primary outcome data at
the prespecified time point; however data were also collected at
other time points, and this was not reported.
We considered that four studies demonstrated high risk of re-
porting bias. Boonyavorakul 2000 provided only raw admission
data, and severity scores were provided only in terms of ’variance.’
Bradshaw 2007, Skobeloff 1989 and Tiffany 1993 provided raw
data for only a subset of outcomes or time points, with remaining
results presented graphically or without variance and with no re-
porting of raw data.
Other potential sources of bias
No additional sources of bias were identified.
Effects of interventions
See: Summary of findings for the main comparison IVMgSO4
for treating adults with acute asthma in the emergency department
Primary outcomes
Hospital admissions
Combining 11 studies (n = 972) revealed a significant reduction
in hospital admissions compared with placebo (OR 0.75, 95%
CI 0.60 to 0.92; high-quality evidence; Analysis 1.1). Some het-
erogeneity that was not statistically significant was observed (I2 =
28%; P value 0.18). In absolute terms, this odds ratio translates to
a reduction of seven hospital admissions for every 100 adults (95%
CI two to 13 fewer) treated with IVMgSO4 (Figure 3). There was
no reason to downgrade for any of the five domains in GRADE
(risk of bias, inconsistency, indirectness, imprecision, publication
bias). Specifically, risk of bias was generally low or unclear across
trials, heterogeneity was not significant, trialsmatched the research
question well, confidence intervals were relatively narrow and al-
most all studies contributed data to the analysis.
17Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. In the control group, 57 of 100 people were admitted to hospital, compared with 50 (95% CI 45 to
55) of 100 for the IV MgSO4 group.
Secondary outcomes
Intensive care admissions
Evidence from one study (Goodacre 2013; n = 752) showed no
significant difference in admission rates between IV MgSO4 and
placebo (OR 2.03, 95% CI 0.70 to 5.89; moderate-quality ev-
idence; Analysis 1.2). The same study reported the number of
participants admitted to the high dependency unit and showed
no significant difference between the two arms (OR 1.05, 95%
CI 0.57 to 1.94; moderate-quality evidence; Analysis 1.3). Both
outcomes contained few events from only one study, so they were
downgraded twice for imprecision, and the quality of evidence was
rated as ’low.’
ED treatment duration
Only one study (Green 1992; n = 452) reported ED treatment
duration and found no significant difference between IV MgSO4
and placebo (MD -4.00, 95% CI -37.02 to 29.02; low-quality
evidence; Analysis 1.4). The outcome was downgraded for risk of
bias and imprecision.
Length of hospital stay (days)
Combining three studies reporting the outcome (n = 949) revealed
no significant difference in time spent in hospital between the IV
MgSO4 and placebo groups (MD -0.03, 95% CI -0.33 to 0.27;
low-quality evidence; Analysis 1.5). The evidence was downgraded
for risk of bias and inconsistency (I2 = 53%; P value 0.10). As
I2 was over the 30% defined in the protocol, we performed a
sensitivity analysis using random effects, which did not change the
conclusions (MD -0.16, 95% CI -0.68 to 0.37).
Readmission
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Too few events were described in only two studies to indicate
whether IVMgSO4 had an effect on readmission to hospital com-
pared with placebo (OR 2.30, 95% CI 0.66 to 7.99; moderate-
quality evidence; Analysis 1.6). No statistical heterogeneity was
noted between the studies (I2 = 0%; P value 0.34), but the out-
come was downgraded for imprecision.
Vital signs
Heart rate
Combining four studies (n = 1195) showed a small significant
reduction in heart rate with IV MgSO4 compared with placebo
(MD -2.37, 95% CI -4.13 to -0.61; moderate-quality evidence;
Analysis 1.7). However a high degree of heterogeneity was ob-
served, which was statistically significant and warranted down-
grading (I2 = 78%; P value 0.004). A sensitivity analysis using
random effects decreased precision significantly, with confidence
intervals including both significant benefit and potential harm of
IV MgSO4 (MD -2.61, 95% CI -6.58 to 1.35).
Respiratory rate
When five studies were combined (n = 1276), IV MgSO4 did
not show a significant reduction in respiratory rate compared with
placebo (MD -0.28, 95% CI -0.77 to 0.20; moderate-quality ev-
idence; Analysis 1.8). Heterogeneity was not significant (I2 = 1%;
P value 0.39), but the evidence was downgraded for imprecision
because confidence intervals included significant benefit and po-
tential harm of the treatment.
Systolic blood pressure
Four studies (Bloch 1995; Bradshaw 2007; Goodacre 2013;
Silverman 2002; n = 1264) reporting systolic blood pressure
showed no difference between IVMgSO4 and placebo (MD 0.08,
95% CI -1.89 to 2.05; moderate-quality evidence; Analysis 1.9).
Heterogeneity was high, and although it was not statistically sig-
nificant, authors considered it large enough to warrant downgrad-
ing for inconsistency (I2 = 51%; P value 0.11). A sensitivity anal-
ysis using random effects did not change the conclusions (MD -
0.73, 95% CI -4.13 to 2.67).
Oxygen saturations
One study reported outcomes separately for those receiving and
those not receiving oxygen (Goodacre 2013). This outcome was
not reported in other studies; therefore we were unable to meta-
analyse the data.
Spirometry
FEV1 (% predicted)
When four studies were combined (Bilaceroglu 2001; Bloch 1995;
Silverman 2002; Singh 2008) (n = 523), significant improvement
in percentage predicted FEV1 was seen in the IV MgSO4 group
comparedwith the placebo group (MD4.41, 95%CI1.75 to 7.06;
high-quality evidence; Analysis 1.10).No significant heterogeneity
was noted among studies (I2= 14%; P value 0.33).
During data analysis, reported standard deviations in Bilaceroglu
2001 were outliers and appeared to be more consistent with stan-
dard error values; the author confirmed that this was the case. In
addition, Bloch 1995 reported no standard deviations; therefore
the standard error of the mean was calculated from the graphs.
PEF (% predicted)
Three studies (Bradshaw 2007; Goodacre 2013; Silverman 2002;
n = 1129) reported PEF (% predicted) and showed a statistically
significant improvement in PEF with IV MgSO4 compared with
placebo (MD 4.78, 95% CI 2.14 to 7.43; high-quality evidence;
Analysis 1.11). Heterogeneity between studies was high but was
not statistically significant (I2 =45%;P value 0.16), so the evidence
was not downgraded. A sensitivity analysis with random effects
did not change our conclusions (MD 5.17, 95% CI 1.15 to 9.19).
On the basis of observed baseline imbalances in the largest study
(Goodacre 2013), a second sensitivity analysis using change from
baseline instead of endpoint means substantially reduced the effect
(MD 1.57, 95% CI -0.55 to 3.69; I2 = 79%, P = 0.009; Analysis
2.5).
PEF (L/min)
Combining eight studies (n = 1460) revealed that IV MgSO4 im-
proved PEF compared with placebo (MD 17.40, 95% CI 8.64 to
26.17; moderate-quality evidence; Analysis 1.12). However sta-
tistically significant heterogeneity between the studies (I2 = 50%;
P value 0.05) warranted downgrading. A sensitivity analysis with
random effects did not change our conclusions (MD 18.35, 95%
CI 4.12 to 32.58). As with the percentage PEF predicted analysis,
a second sensitivity analysis using Goodacre 2013 change from
baseline substantially reduced the magnitude of effect (MD 9.44,
95% CI 2.07 to 16.81; I2 = 68%, P = 0.003; Analysis 2.6).
Validated symptom scores
Five studies used symptom scales, all measuring breathlessness (n =
1237). The Borg Dyspnoea Scale was used by four studies (Bloch
1995; Porter 2001; Silverman 2002; Singh 2008), and Goodacre
2013 used a VAS for breathlessness. Data for the Borg Dyspnoea
Scale revealed no significant change with IV MgSO4 compared
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with placebo (MD -0.22, 95% CI -0.55 to 0.12; high-quality
evidence; Analysis 1.13), and no significant heterogeneity between
studies was noted (I2 = 0%; P value 0.82).
Similarly, Goodacre 2013 reported no significant change in VAS
score with IV MgSO4 compared with placebo (MD -3.00, 95%
CI -7.09 to 1.09).
Adverse events
The most commonly cited adverse events were flushing, fatigue,
nausea and headache; some study authors also commented on
hypotension.
Bilaceroglu 2001 reported flushing in 42% of those receiving IV
MgSO4 versus no flushing in the placebo group. Although paraes-
thesia, vertigo and hypotension were also reported, nomarked dif-
ferences between treatment and placebo arms were observed.
Bloch 1995 reported that 58% of those receiving IV MgSO4 re-
ported adverse events, including the sensation of flushing, fatigue
and burning at the IV site, with one participant experiencing tran-
sient urticaria in the upper extremities.
Bradshaw 2007 reported minor adverse events in 8% of those
receiving IVMgSO4 (headache, flushing, dizziness), with only one
participant in the placebo arm reporting flushing (1.5%).
Goodacre 2013 reported the rate of adverse events (death, arrhyth-
mia, cardiac arrest, non-invasive ventilation, intubation, other) as
13% in the treatment group compared with 10% in the placebo
group, although these rates fall almost entirely in the ’other’ cate-
gory. One death of an unspecified cause (1%) was reported in the
IV MgSO4 group compared with none in the placebo group. No
other trials reported deaths. Goodacre 2013 reported commonly
cited adverse events as a separate category and revealed a statisti-
cally significant increase in adverse events in the IVMgSO4 group
(OR 1.68, 95% CI 1.07 to 2.63; P value 0.025).
Both Porter 2001 and Singh 2008 reported that the difference
between rates of adverse events (including deep tendon reflexes)
among participants given IV MgSO4 versus placebo was not sta-
tistically significant.
Skobeloff 1989 reported higher rates of fatigue (32% vs 11%),
warmth (26%) and lightheadedness (5%) in the IVMgSO4 group,
but the numbers in this study were small.
With respect to blood pressure, Bilaceroglu 2001 reported hy-
potension in 5% versus 3% of participants in the treatment versus
placebo groups, whilst Goodacre 2013 reported 8% versus 6%,
respectively. Bradshaw 2007 reported a non-significant trend for
decreasing blood pressure at 60 minutes, and Singh 2008 reported
no hypotension.
Subgroup analyses
Baseline severity (moderate, severe and life-threatening
exacerbations)
The test for subgroup differences revealed no statistical hetero-
geneity between the three severity subgroups (I2 = 0%; P value
0.73), and between-trial heterogeneity was significant within all
three subgroups (I2 = 50%; P value 0.01).
Mean age (≤ and > 65 years)
Most studies included participants over age 65, but all population
mean ages were much lower than the cutoff. As we did not have
access to individual participant data within the trials, we were
unable to draw any conclusions regarding potential differential
effects of IV MgSO4 due to age.
Co-medications (with and without nebulised ipratropium
bromide)
The test for subgroup differences showed no significant differences
between the four studies that administered nebulised ipratropium
bromide as a co-medication and those that did not (I2 = 0%; P
value 0.82). Between-trial heterogeneity was not statistically sig-
nificant within either of the two subgroups (I2 = 28%; P value
0.18).
Sensitivity analysis
Studies at high risk of bias for blinding
When three studies that were given a ’high’ or ’unclear’ rat-
ing for blinding were removed (Bilaceroglu 2001; Green 1992;
Matusiewicz 1994), the pooled effect for hospital admissions was
slightly larger in favour of IV MgSO4 (OR 0.72, 95% CI 0.57 to
0.91; Analysis 2.3). Heterogeneity was slightly larger than in the
main analysis, but this difference was not statistically significant
(I2 = 35%; P value 0.15).
Unpublished data
Of the two studies for which only a conference abstract was avail-
able, one reported hospital admissions (Matusiewicz 1994).When
this study was removed from the primary outcome, themagnitude
of the effect in favour of IV MgSO4 was slightly increased (OR
0.73, 95% CI 0.58 to 0.91), but this did not change the conclu-
sions. Some heterogeneity that was not significant was reported (I
2 = 32%; P value 0.15).
D I S C U S S I O N
Summary of main results
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Fourteen studies met the inclusion criteria, randomly assigning
2313 people with acute asthma to the comparisons of interest in
this review. A recent large study (Goodacre 2013) accounted for a
large proportion of the total number of participants (n = 752).
The included studies were mostly randomised, double-blinded
trials comparing 1.2 g or 2 g IVMgSO4 versus a matching placebo
infusion. All of these studies included participants who had an
exacerbation of asthma, although definitions and inclusion criteria
varied. Ten studies included only adults; four included adults and
children andwere includedbecause themean agewas over 18 years.
Inclusion criteria varied, and studies assigned a level of severity
to participants, which we then verified against BTS/SIGN 2012
criteria, confirming that all studies included exacerbations of at
least moderate severity.
Eleven studies could be included in the primary analysis and
showed that IV MgSO4 reduced hospital admissions compared
with placebo (OR 0.75, 95% CI 0.60 to 0.92; I2 = 28%; P value
0.18; n = 972; high-quality evidence). In absolute terms, this odds
ratio translates into a reduction of seven hospital admissions for
every 100 adults (95%CI two to 13 fewer) treatedwith IVMgSO4
(Figure 3). The test for subgroup differences did not reveal sta-
tistical heterogeneity between the three severity subgroups (I2 =
0%; P value 0.73), or between the four studies that administered
nebulised ipratropium bromide as a co-medication and those that
did not (I2 = 0%;, P value 0.82). Sensitivity analyses removing
unpublished data and studies at high risk for blinding from the
primary analysis did not change conclusions; this increased our
confidence in the effect.
Within the secondary outcomes, evidence of high and moderate
quality across three spirometric indices suggested some improve-
ment in lung function with IV MgSO4; however the clinical sig-
nificance of the size of these effects is uncertain, and baseline im-
balances in the largest study reduced our confidence in some of
the findings. Although close, the mean difference in PEF (L/min)
found in this meta-analysis did not reach the minimal clinically
important difference (MCID) defined by Santanello 1999 (18.79
L/min). There are no accepted MCIDs for the percentage pre-
dictedmeasures reported inmost of the trials.Mean FEV1 in litres,
for which an MCID does exist, was reported in only two of the
14 trials.
No difference between IV MgSO4 and placebo was found for
most of the non-spirometric secondary outcomes, all of which
were rated of low or moderate quality (intensive care admissions,
ED treatment duration, length of hospital stay, readmission, res-
piration rate, systolic blood pressure).
Adverse events were inconsistently reported and were not meta-
analysed. The most commonly cited adverse events in the IV
MgSO4 groups were flushing, fatigue, nausea and headache and
hypotension. However we found no significant difference in blood
pressure between the IV MgSO4 and placebo groups.
Overall completeness and applicability of
evidence
A large degree of variation between prescribing procedures was
evident in the trials, but doses used in the included studies are in
accord with current BTS/SIGN 2012, GINA 2011 and NACA
2006 guidelines. However, the treatment protocols differed as to
when the decision to administer IVMgSO4 was made; the dosage,
frequency and form of co-medications and the order in which
the medications were administered in relation to one another. We
suspect that differences between individual EDs both within and
among countries were significant, and insufficient reporting in the
trials themselves further complicated interpretation of the sub-
group analysis for co-medications. As such, although no evidence
suggested a difference in the efficacy of IV MgSO4 delivered in
settings where ipratropium bromide was prescribed, we cannot
exclude the possibility that other combinations of co-medications
may significantly alter the effectiveness of IV MgSO4. Moreover,
as almost all of the studies administered short-acting beta2-ago-
nists, oxygen and IV corticosteroids before MgSO4, the evidence
is suitably applied to situations for which these medications have
already been prescribed. Doses of magnesium used and method
and rate of delivery were relatively consistent across studies (1.2 g
to 2 g via 15 to 30-minute infusion), so it is not clear whether the
same effect would be observed with alternative administrations
(e.g. higher dose, bolus).
The definition of hospital admission may have varied between the
healthcare settings in which these studies were carried out, and
this was not clearly defined in the studies. We accept that variation
exists in the broader health and economic environments and in
health infrastructures, such as the use of clinical decision making
or observation wards, and that this is likely to have influenced
the decision to admit. This variation is likely to have introduced
heterogeneity in the primary outcome.
The previous version of this review (Rowe 2009) suggested the
possibility of greater efficacy of treatment in more severe exacerba-
tions; this partially informed our decision to perform a subgroup
analysis based on severity. We did not find a statistically signifi-
cant difference between the three severity subgroups; however, the
method that we used to allocate baseline severity had limitations.
We based this classification on BTS/SIGN 2012 criteria, but re-
porting of baseline metrics on which this guidance is based was
insufficient in several studies. In studies that subdivided the pop-
ulation on the basis of severity (Bilaceroglu 2001; Bloch 1995;
Bradshaw 2007), subgroups with a more severe condition gained
greater benefit with respect to hospital admission. This suggests
that within-study subgroups may serve as a more reliable way of
assessing severity as an effect modifier by controlling for differ-
ences in other variables that may exist between study protocols.
Wewere unable to draw conclusions regarding the potential effects
of age on study outcomes, as none of the studies recruited older
adults. It is possible that diagnosis in this age group would be
complicated by important co-morbidities (e.g. chronic obstructive
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pulmonary disease (COPD)), and that these might also affect the
safety and effectiveness of IV MgSO4. As such, it is likely that the
conclusions of this review are not applicable to this population, or
to children younger than the age of 12.
Several outcomes showed significant statistical heterogeneity
among studies that was not accounted for by subgrouping results
by severity of exacerbations (heart rate (HR), systolic blood pres-
sure (BP), PEF in L/min, length of hospital stay). For HR, systolic
BP and PEF in L/min, variation may be explained in part by when
and how the measurement was taken, measurement error and the
influence of co-medications. Length of hospital stay is highly de-
pendent on local hospital guidelines and procedures.
We were unable to meta-analyse data related to adverse events
and therefore could not draw conclusions about the safety of IV
MgSO4 in asthma. Some commonly cited adverse events were
consistently reported among the studies; however, the methods of
recording adverse events appeared unsystematic.
Quality of the evidence
WeusedGRADEpro software to assess the quality of all outcomes;
this assessment is summarised in the text and in the Summary
of findings for the main comparison. Most outcomes were not
downgraded for risk of bias, and in the two cases in which this was
done, the decision was related primarily to insufficient blinding.
It is unclear how this may have affected results for the primary
outcome (i.e. decision to admit), but a sensitivity analysis exclud-
ing studies in which blinding was insufficient or unclear showed
that this bias is unlikely to have significantly affected the pooled
estimate.
Several outcomes were downgraded for inconsistency, that is, sta-
tistical heterogeneity, between studies. In these cases we performed
sensitivity analyses using a random-effects model, which did not
alter conclusions. The clinical source of the statistical heterogene-
ity remains unclear in most cases, as planned subgroup analyses
were performed only on the primary outcome. Most of the sec-
ondary outcomes for which heterogeneity was observed contained
a small number of studies; therefore it is unlikely that subgrouping
of results would have allowed a meaningful distinction between
severity or co-medication subgroups.
Studies included in this review were directly relevant to our review
question with respect to participants recruited, interventions and
comparisons provided, healthcare setting selected, and outcome
measures used, so none of the evidence was downgraded for indi-
rectness.
Four outcomes were downgraded for imprecision on the basis
of their wide confidence intervals (intensive care unit (ICU) ad-
mission, ED treatment duration, PEF in L/min, respiratory rate
(RR)). In each case the review authors made a clinical judgement
regarding the minimal clinically important difference in relation
to the confidence intervals. Moreover, with the exception of ED
treatment duration, evidence from related outcomes (e.g. other
spirometric measures) helped us draw conclusions when impreci-
sion was due to a small number of participants or events.
No outcomes were downgraded for publication bias, although sev-
eral of the secondary outcomes included a small number of stud-
ies. No incidences were identified in which studies stated out-
comes and failed to report them, but this was generally a result
of insufficient reporting of intended outcomes and the fact that
the studies could not be linked to trial registrations. Most studies
were conducted before adherence to trial registration or reporting
standards was common practice, so in most cases we were unable
to definitively judge whether the evidence was compromised as a
result of deliberate or inadvertent selective reporting.
To resolve uncertainties related to risk of bias and missing data, we
made an effort to contact all study authors. We received additional
data from four of these authors (Bilaceroglu 2001; Bloch 1995;
Goodacre 2013; Singh 2008), were unable to obtain current con-
tact details for two (Matusiewicz 1994; Porter 2001) and received
no response from the remaining eight.
Potential biases in the review process
We made every effort to adhere to Cochrane methods during the
review process. All study characteristics and numerical data were
extracted by at least two review authors, and discrepancies were
resolved through discussion. The same was true for risk of bias
ratings, and none of the review authors have conflicting interests.
We performed relatively broad searches that were screened by at
least two review authors independently, and we included studies
regardless of language of publication. As a result, It is unlikely
that any published studies were missed during study selection. In
addition, review authors attempted to contact all study authors to
clarify studymethodology or to obtain additional datawhendetails
were not included in the published reports. We received detailed
replies and additional data from four study authors, but in most
cases, it was unclear whether study authors had failed to receive the
request or were simply unable to provide the information required.
The subgroup analysis based on exacerbation severity introduced
the potential for internal bias, despite efforts to remove bias by
consultation with an independent fourth party. Although we were
transparent in the method of classification, an element of subjec-
tivity due to reporting standards was noted in some trials; this
reduced our confidence in the subgroup findings.
Agreements and disagreements with other
studies or reviews
Our literature search identified five systematic reviews with meta-
analyses comparing use of IV MgSO4 versus placebo in adults
with acute asthma (Alter 2000; Mohammed 2007; Rodrigo 2000;
Rowe 2009; Shan 2013). One of these, Rowe 2009, was a pre-
vious Cochrane review, and Shan 2013, the most recent research
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synthesis, included the greatest number of trials (n = 16), 10 of
which are included in this review.
The main outcomes analysed were hospital admissions and spiro-
metric data. None of the existing reviews found a statistically sig-
nificant reduction in hospital admissions across all severity sub-
groups. However Rowe 2009 found a significant reduction in hos-
pital admissions within the more severe group (OR 0.10, 95% CI
0.04 to 0.27) and suggested that IV MgSO4 might play a role in
these more severe exacerbations. Hospital admission data for Shan
2013 were on the border of statistical significance (P value 0.06).
Alter 2000 and Shan 2013 reported significant improvement in
pooled spirometricmeasures for those receiving IVMgSO4 , whilst
Mohammed 2007 reported weak evidence to support this (SMD
0.25, 95% CI -0.01 to 0.51; P value 0.05). Pooled analyses in
Rodrigo 2000 andRowe 2009 showedno significant improvement
in lung function for those given IV MgSO4.
In keeping with these reviews, we found evidence that IV MgSO4
improves lung function on a variety of spirometricmeasures.How-
ever, our findings differ in that when all data regardless of severity
criteria were pooled, a statistically significant reduction in hospital
admissions was seen among those treated with IVMgSO4. We did
not draw firm conclusions regarding the extent to which severity
of exacerbation affects the efficacy of IV MgSO4 because differ-
ences in the ways the studies were conducted made it difficult to
assess the effect of exacerbation severity independent of other ef-
fect moderators.
Several reasons may account for the discrepancies between our
conclusions and those of previous evidence syntheses. Unlike some
previous systematic reviews (Alter 2000;Mohammed 2007; Rowe
2009; Shan 2013), our inclusion criteria did not include pae-
diatric trials. Several additional trials have been published since
the previous version of this review, and this warranted synthesis-
ing of data for adults separately from data for children (Bijani
2001; Bilaceroglu 2001; Boonyavorakul 2000; Bradshaw 2007;
Del Castillo Rueda 1991; Goodacre 2013; Matusiewicz 1994;
Porter 2001; Singh 2008). One of these trials, Goodacre 2013,
is a recent randomised controlled trial with a large sample size;
it accounted for a significant proportion of the total weight in
several of our analyses. Evidence for the use of IV MgSO4 in the
paediatric population will be analysed in a separate Cochrane re-
view, which is currently in production. Some previous syntheses
have included trials of nebulised magnesium sulfate (Mohammed
2007; Rodrigo 2000; Shan 2013), which we did not include, as
this is the subject of an existing Cochrane review (Powell 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides evidence that a single infusion of 1.2 g or 2 g
IVMgSO4 over 15 to 30 minutes reduces hospital admissions and
improves lung function in adults with acute asthma who have not
responded sufficiently to oxygen, nebulised short-acting beta2-ag-
onists and IV corticosteroids. Differences in the ways the trials
were conducted made it difficult to assess whether the severity of
the exacerbation, or additional co-medications, altered the treat-
ment effect of IV MgSO4. Evidence for other measures of benefit
and safety was limited.
Implications for research
Studies conducted in these populations should clearly define base-
line severity parameters and systematically record adverse events.
Studies recruiting participants with exacerbations of varying sever-
ity should consider subgrouping results on the basis of accepted
severity classifications.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bijani 2001
Methods Design: randomised, double-blind, placebo-controlled study based in Iran. No infor-
mation provided regarding location of trial or dates when it was carried out
Final measurement of outcomes performed at 180 minutes with participants followed
for 6 hours
Participants Population: 81 participants randomly assigned to control (33) or IV MgSO4 infusion
(48)
Inclusion criteria: asthmatic individuals aged 12 to 85 years with an exacerbation of
asthma and apeak expiratory flow (PEF) <200L/minwhohad takenbronchodilators and
corticosteroids and required assisted ventilation. All participants who did not respond
to treatment during the next 6 hours selected for investigation
Exclusion criteria: not reported
Interventions Control group: 100 mL normal saline infused over 30 to 45 minutes after 6 hours of
no response to standard treatment
IV MgSO4 group: 25 mg/kg in 100 mL normal saline infused over 30 to 45 minutes
after 6 hours of no response to standard treatment
Co-interventions: All participants received oxygen, nebulised oxygen, nebulised salbu-
tamol, IV aminophylline and corticosteroids
Outcomes PEF; breathing rate; cyanosis; diaphoresis; use of respiratory muscles; ABGs all measured
at baseline
Notes Baseline severity of population: life threatening (based on 31% predicted PEF, respi-
ration rate 35 breaths per minute)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ but no information provided
as to how this was done
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double-blind’ study; IV MgSO4 and nor-
mal saline in ’identical containers’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ’Double-blind’ study; investigators report
that ’decoding was done at the completion
of the study.’ However the study authors do
not specifically report who was measuring
outcomes
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Bijani 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawal rates provided
Selective reporting (reporting bias) Low risk Everything reported except ABG (but this
is not a primary outcome). No protocol
available. Otherwise all outcomes well re-
ported
Bilaceroglu 2001
Methods Design: Randomised, single-blind trial based in Turkey. Trial was carried out in a spe-
cialist respiratory hospital in Turkey between December 1995 and December 1996
Final measurement of outcomes performed at 210 minutes, and participants followed
up for 1 week afterward
Participants Population: 81 participants randomly assigned to Group 1-moderate asthma (PEF >
40%) (n = 50) or Group 2-severe asthma (PEF < 40%) (n = 31) Within Group 1,
participants randomly assigned toplacebo (salbutamol +placebo) (n = 27) or intervention
(salbutamol + magnesium) (n = 23). Within Group 2, participants randomly assigned
to placebo (salbutamol + corticosteroid + placebo) (n = 14) or intervention (salbutamol
+ corticosteroid + magnesium) (n = 17)
Inclusion criteria: Asthmatic participants (defined by American Thoracic Society Cri-
teria) aged 6 to 65 years (average age 35 years) with PEF increasing by < 50% and/or
FEV1 < 75% after a single salbutamol nebuliser (2.5 mg salbutamol in 2.5 mL saline)
Exclusion criteria: diabetes mellitus, congestive heart failure, hypertension, chronic
renal failure,
fever > 38 ºC, pneumonia, under mechanical ventilation and/or having suspicion of
pregnancy. Furthermore, participants with > 50% increase in PEF after beta-agonist
inhalation, or with FEV1 higher than 75% of predicted value at presentation or after
inhaled beta-agonist (response to treatment)
Interventions Control group: Group 1 given salbutamol + placebo (100 cc of 5% dextrose solution).
Group 2 given salbutamol (2.5 mg nebulised) + corticosteroid (125 mg prednisolone) +
placebo (100 cc of 5% dextrose solution). In both groups, these were given at the 30th
minute of the participant’s arrival
IV MgSO4 group: Group 1 given salbutamol + 2 mg IV MgSO4 in 100 cc dextrose
solution. Group 2 given salbutamol (2.5 mg nebulised) + corticosteroid (125 mg pred-
nisolone) + 2 mg MgSO4 in 100 cc dextrose solution. Both groups given treatment at
the 30th minute of their arrival
Co-interventions: All participants received oxygen if PaO2 < 60mmHg
Outcomes PEF, FEV1 and hospitalisation, length of hospital stay; change in systolic arterial pressure;
change in respiration rate; dyspnoea; blood gases; serum Mg; calcium; specific adverse
events
Notes Baseline severity of population: Moderate and severe groups in the trial reclassified as
severe and life threatening, respectively, for consistency with other study classifications
and BTS guidelines (BTS/SIGN 2012)
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Bilaceroglu 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised’ study using 1:1 tables but no
other information provided regarding se-
quence generation
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ’Single-blind’ study. Only participants
blinded to the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ’Single-blind’ study. Only participants
blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clear withdrawal rates provided. No with-
drawals described after suitable participants
(n = 81) were identified for randomisation.
(Data from all excluded participants (n =
218) before randomisation not used in the
analysis)
Selective reporting (reporting bias) Unclear risk Results given for stated outcomes, but some
data given only in graph format. Raw data
not provided
Bloch 1995
Methods Design: randomised, double-blind, placebo-controlled study based in the USA. Trial
carried out in 2 EDs of a voluntary and a university hospital in the USA between August
1990 and December 1991
Final measurement of outcomes performed at 240 minutes and participants followed up
for 7 days
Participants Population: 149 participants randomly assigned to control (68) or IV MgSO4 (67)
Inclusion criteria: asthmatic participants aged 18 to 65 years, with an exacerbation
defined as FEV1 < 75% predicted before and after a single dose of salbutamol
Exclusion criteria: past medical history of congestive cardiac failure, diabetes mellitus,
angina or chronic kidney disease; temperature > 38 ºC; pregnancy; pneumonia; requiring
intubation; unable to perform spirometry; unable to consent; FEV1 > 75% before or
after single dose of salbutamol
Interventions Control group: 50 mL of 0.9% normal saline given 30 minutes after entry and infused
over 20 minutes
IV MgSO4 group: 2 g IV MgSO4 in 50 mL 0.9% normal saline given 30 minutes after
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Bloch 1995 (Continued)
entry and infused over 20 minutes
Co-interventions: All participants received Inhaled albuterol (2.5 mg in 2.5 mL normal
saline) on arrival. If FEV1 < 40% predicted, or if participants had received oral corticos-
teroids within the past 6 months, they received 125 mg IV methylprednisolone within
30 minutes of presentation. Some participants were already taking theophylline before
the time of presentation
Outcomes Hospitalisation rate; FEV1 at 2 hours after baseline; repeat hospitalisations; respiratory
rate; heart rate; systolic blood pressure; Borg score; wheeze score; adverse events
Notes Funded by the Nina Weisman Pulmonary Research Fund
Baseline severity of population: moderate and severe groups in the trial reclassified as
severe and life threatening, respectively, for consistency with other study classifications
and BTS guidelines (BTS/SIGN 2012)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned by the pharmacy using
’computer-generated tables’
Allocation concealment (selection bias) Low risk ’All physicians were blinded to the ran-
domisation that was done by the pharmacy’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double -blind’ but no description of how
interventions were disguised
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No subjective assessor-rated outcomes, and
the investigators remained blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported: ’Fourteen patients
were excluded after randomisation.’ ’Four
patients were included as an intention to
treat because the protocol was violated…’
’In six patients their baseline FEV1was un-
available and these were included in the
analysis as a whole and excluded from sub-
group analysis’
Overall small attrition numbers
Selective reporting (reporting bias) Low risk Published report provided data only at one
of the prespecified time points; FEV1 was
provided graphically, but the study author
provided additional data upon request
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Boonyavorakul 2000
Methods Design: randomised, double-blind, placebo-controlled study based in Thailand. Trial
carried out in a single ED between March and November 1997
Final measurement of outcomes performed at 240 minutes with no further follow-up of
participants
Participants Population: 34 participants randomly assigned to control (16) or IV MgSO4 (17)
Inclusion criteria: asthmatic individuals aged 15 to 65 years with acute severe asthma,
defined as having a severity score > 4, who consented to enter the trial
Exclusion criteria: co-morbidities including ischaemic heart disease, hypertension, di-
abetes mellitus, chronic kidney disease, infection or pregnancy; or a FISCHL Index < 4
Interventions Control group: 2 mL of sterile water in 50 mL 0.9% normal saline
IV MgSO4 group: 2 g of Mg SO4 in 50 mL 0.9% normal saline
Co-interventions: All participants received 5 mg intravenous dexamethasone, 2.5 mg
nebulised salbutamol at 0, 20, 40, 60 minutes and oxygen via mask if necessary
Outcomes Hospitalisation rate; severity score FISCHL Index at 0, 60, 120, 180, 240 minutes
(comprising pulse rate, respiratory rate, PEF, dyspnoea, accessory muscle use and wheeze)
Notes Baseline severity of population: life threatening (based on comparison of vital stats [HR
125 bpm, respiration rate 33] with other studies with multiple baseline measurements)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using a ’computer gen-
erated random list’
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study. ’Study investigators
and patients were blind to whether they ad-
ministered/received MgSO4 or placebo’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Only 2 physicians took responsibility for
caring for patients in ED. They measured
all clinical data and made the decision re-
garding admission. They were blinded and
the protocol was not violated during the
study’
Incomplete outcome data (attrition bias)
All outcomes
Low risk ’One patient in the placebo group didn’t
consent and so was removed from the
group.’ Equal numbers of withdrawals
from both groups (17 magnesium and 16
placebo)
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Boonyavorakul 2000 (Continued)
Selective reporting (reporting bias) High risk Incomplete reporting: only the admission
data given. Severity scores given only in
terms of ’variance’ and no raw data pro-
vided
Bradshaw 2007
Methods Design: randomised, double-blind, placebo-controlled study based in Edinburgh. Trial
carried out in a teaching hospital. No information provided regarding the dates of the
study
Final measurement of outcomes performed at 60 minutes and no follow-up of partici-
pants reported
Participants Population: 129 participants randomly assigned to control (67) or IV MgSO4 (62)
Inclusion criteria: asthmatic individuals aged 16 years and older, with asthma exacer-
bation defined as PEF < 75%
Exclusion criteria: co-morbidities including chronic obstructive pulmonary disease,
pneumonia, congestive cardiac failure, coronary artery disease, chronic kidney disease,
hypertension or pregnancy; participants who are unable to carry out peak flow measure-
ments
Interventions Control group: 50 mL 0.9% normal saline infused over 15 minutes
IV MgSO4 group: 1.2 g IV MgSO4 in 50 mL 0.9% normal saline infused over 15
minutes
Co-interventions: All participants received 35% oxygen, 5 mg nebulised salbutamol,
500 mcg nebulised ipratropium bromide, 200 mg IV hydrocortisone
Outcomes % predicted PEF at 60 minutes (repeated at 15, 30, 45 and 60 minutes), hospital
admission rates (decision made at 60 minutes), blood pressure and pulse at 60 minutes
Notes Baseline severity of population: Moderate, severe and life-threatening classifications
within the trial were not changed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomised using random number gen-
eration under the control of hospital phar-
macy’
Allocation concealment (selection bias) Low risk Randomisation done by pharmacy and
physicians remained blinded
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind, placebo controlled study’.
IV MgSO4 and placebo ’identical in ap-
pearance’
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Bradshaw 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No subjective assessor-rated outcomes (3 ×
PEF), and the investigators remainedblind.
The ’decision to admit/discharge was made
by the attending physician’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Well reported. 21 participants excluded
prior to randomisation. None after that
Selective reporting (reporting bias) High risk Incomplete reporting- primary and sec-
ondary outcomes given at 60 minutes but
not at other intervals (data given in graph
format but no raw data available, making
analysis difficult)
Del Castillo Rueda 1991
Methods Design: randomised, no information on blinding, placebo-controlled study based in
Spain. Trial carried out in one hospital in Madrid
Information regarding duration of the trial and follow-up of participants not provided
Participants Population: 16 participants randomly assigned to control (6) and IV MgSO4 (10)
Inclusion criteria: participants with acute asthma. No details provided regarding age or
how acute asthma was defined
Exclusion criteria: not reported
Interventions Control group: not reported
IV MgSO4 Group: 1.2 g of IV MgSO4 in physiological fluid infused over 20 minutes
Co-interventions: All participants received corticosteroids and beta-2 agonists
Outcomes PEF; ABG; hospitalisation rate; length of stay; adverse events
Notes Abstract only
Baseline severity of population: unknown, but did not contribute data to the primary
analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Authors describe the study as ’randomised,
double blind,’ but no details given about
the blinding process. Difficult to comment
based on the abstract alone
Allocation concealment (selection bias) Unclear risk No information provided. Difficult to
comment based on the abstract alone
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Del Castillo Rueda 1991 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided. Difficult to
comment based on the abstract alone
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided. Difficult to
comment based on the abstract alone
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided. Difficult to
comment based on the abstract alone
Selective reporting (reporting bias) Unclear risk No information provided. Difficult to
comment based on the abstract alone
Goodacre 2013
Methods Design: randomised, double-blind, placebo-controlled study based in the UK. Trial
carried out in the EDs of 34 hospitals across the UK between 30 July 2008 and 30 June
2012
Final measurement of outcomes performed at 120 minutes; however decision to admit
made at 240 minutes and participants followed up for 1 month
Participants Population: 1109 participants randomly assigned to control (364) and IVMgSO4 (406)
and one other group that was not relevant to our study (nebulised magnesium; n = 339)
Inclusion criteria: asthmatic individuals aged 16 years and older with severe acute
asthma (defined as PEF < 50%, respiratory rate > 25 breaths/min, heart rate > 110 bpm,
unable to complete sentences)
Exclusion criteria: life-threatening exacerbations, contraindications to study drugs (e.
g. pregnancy, chronic kidney disease, liver failure, heart block, high serum magnesium
levels), participants who are unable to consent, previous participants in the 3Mg trial,
those who had received magnesium in the previous 24 hours
Interventions Control group: 100 mL 0.9% normal saline infused over 20 minutes
IV MgSO4 group: 2 g MgSO4 in 100 mL 0.9% normal saline infused over 20 minutes
Co-interventions: All participants received oxygen, 5mgnebulised salbutamol, 500mcg
nebulised ipratropium bromide and oral prednisolone during recruitment, followed by 5
mg salbutamol added to each trial nebuliser. Other treatments allowed at the discretion
of the clinician
Outcomes Hospital admissions (after ED treatment or within the next 7 days); participant breath-
lessness (VAS score), mortality; adverse events; use of ventilation or respiratory support
Notes Fundedby theUKNational Institute forHealthResearchHealthTechnology Assessment
Programme
Baseline severity of population: We classified baseline severity as moderate, based on
PEF of 433 L/min and PEF percentage predicted of 52%
Risk of bias
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Goodacre 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using telephone or In-
ternet randomisation system managed by
Sheffield Clinical Trials Research Unit
Allocation concealment (selection bias) Low risk ’Participants were allocated to numbered
treatment packs kept in the ED’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind placebo controlled study.’
Numbered treatment packs used. Not clear
whether these were identical in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Participants, hospital staff and research
staff were masked to allocated treatment’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Well documented: ’25 withdrew without
starting trial drug, were recruited in error or
could not be allocated to a treatment pack’
Selective reporting (reporting bias) Low risk Primary outcomeswell reported in the pub-
lished paper, but no information provided
regarding clinical data (e.g. BP, RR, HR)
or participant satisfaction/QOL data (po-
tentially reported elsewhere). However the
author did supply all of this information on
request
Green 1992
Methods Design: prospective unblinded trial (no placebo and unclear whether randomised) based
inCalifornia, USA. Trial carried out in a single EDof an urban teaching hospital between
29 March 1990 and 21 March 1991
Final measurement of outcomes time point unclear
Participants Population: 137 participants allocated to IV MgSO4 treatment or no IV MgSO4 treat-
ment on alternate days of the week
Inclusion criteria: asthmatic individuals aged 18 to 65 years with an exacerbation of
asthma (no further definition)
Exclusion criteria: co-morbidities including ischaemic heart disease, hypertension,
angina, congestive cardiac failure, heart block, chest pain, metastatic cancer, chronic kid-
ney disease, temperature > 38.3 ºC, blood pressure < 120 systolic, pregnancy, pneumonia
or requiring intubation
Interventions Control group: no IV MgSO4 given
IV MgSO4 Group: 2 g IV MgSO4 in 50 mL D5W over 20 minutes within 45 minutes
of treatment initiation
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Green 1992 (Continued)
Co-interventions: All participants received oxygen, 2.5 mg inhaled albuterol, 125 mg
IV methylprednisolone. Other medications (e.g. theophylline, injectable beta-agonists,
epinephrine) were allowed at the discretion of the attending physician
Outcomes Hospitalisation rate; ED treatment time (for those discharged); adverse events; relapse
rate; PEF change from baseline; length of hospital stay
Notes Baseline severity of population: severe (based on low PEF L/min 143 and high vital
stats, HR 108 and respiration rate 29)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk ’Patients presenting on odd days were given
magnesium and those on even days did not
receive magnesium’
Allocation concealment (selection bias) High risk Allocation dependent on the days they pre-
sented. Unblinded and not randomised
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ’Physicians were not blinded to patient ran-
domisation; however, patients and respira-
tory therapists were unaware that a study
was being performed’
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Respiratory therapists (who were measur-
ing the PEF) ’were unaware that a study
was going on,’ but no formal blinding at all
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reported as follows: 217 participants in to-
tal. 80 were repeats and so were excluded
(although it is unclear from which groups
these came), and 17 others were removed
from data analysis because of misplaced
records (total 97/217).No evidence of ITT.
Final group sizes of quite equal size: 58 and
62
Selective reporting (reporting bias) Unclear risk All outcome data given but not clearly de-
scribed as primary or secondary outcomes
in the initial methodology
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Matusiewicz 1994
Methods Design: unclear. Based in Scotland but unclear as to location where the trial was carried
out and during what dates
Final measurement of outcomes performed at 60 minutes and information about follow-
up of participants not provided
Participants Population: 131 participants allocated to control (67) or IV MgSO4 (64)
Inclusion criteria: Adults (age not specified) with acute severe asthma (defined as PEF
< 250 or 50% of best previous PEF)
Exclusion criteria: not reported
Interventions Control group: 50 mL 0.9% normal saline infused over 15 minutes
IV MgSO4 group: 1.2 mg IV MgSO4 in 50 mL 0.9% normal saline infused over 15
minutes
Co-interventions: All participants received 5 mg nebulised salbutamol, 500 mcg neb-
ulised ipratropium bromide, oxygen, 200 mg IV hydrocortisone. Aminophylline was
given at the discretion of the attending physician
Outcomes PEF at 15, 30, 45, 60 minutes; hospitalisation rate
Notes Baseline severity of population: We have classified this population as severe based on
inclusion criteria of PEF < 250 L/min and < 50% predicted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided. Difficult to
comment based on the abstract alone
Allocation concealment (selection bias) Unclear risk No information provided. Difficult to
comment based on the abstract alone
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk ’Double blind placebo controlled parallel
group study.’ No mention of randomisa-
tion nor details of blinding. Difficult to
comment based on the abstract alone
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided. Difficult to
comment based on the abstract alone
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided. Difficult to
comment based on the abstract alone
Selective reporting (reporting bias) Unclear risk No information provided. Difficult to
comment based on the abstract alone
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Porter 2001
Methods Design: randomised, double-blind, placebo-controlled trial based in Philadelphia, USA.
Trial carried out in a single urban ED, the dates of which are not specified
Final measurement of outcomes performed at 60 minutes with no follow-up of partici-
pants
Participants Population: 42 participants randomly assigned to control (24) and IV MgSO4 (18)
Inclusion criteria: asthmatic individuals aged 18 to 55 years with an exacerbation (de-
fined as PEF < 100 or < 25% predicted) and able to consent
Exclusion criteria: co-morbidities including pneumonia, chronic kidney disease, con-
gestive cardiac failure, previous myocardial infarction, hypertension, pregnancy or pos-
sibly requiring intubation
Interventions Control group: 50 mL 0.9% normal saline given immediately
IV MgSO4 group: 2 g MgSO4 in 50 mL 0.9% normal saline given immediately
Co-interventions: All participants received 2.5 mg nebulised albuterol sulfate, 125 mg
IV methylprednisolone, oxygen and repeated albuterol every 20, 40 and 60 minutes
Outcomes PEF (at 60 minutes), hospitalisation rate; Borg score; adverse effects of hypotension and
hyporeflexia
Notes Baseline severity of population: life threatening (based on PEF 88.5 L/min and high
vital stats HR 110 and respiration rate 31)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomised using a random number gen-
erator which assigned the code’
Allocation concealment (selection bias) Low risk ’Enrolment packs containing data record-
ing sheets and study solutions in random
order were prepared by the Pharmacy.’
Saline and magnesium identical in appear-
ance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind’ study. ’Investigators, other
caretakers and patients were unaware of
contents of the study solution’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Investigators, other caretakers and patients
were unaware of contents of the study so-
lution’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No attrition data specifically reported.
Comment that the same participant pre-
senting more than once was not used, in-
dicating that investigators always used the
first presentation for analysis
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Porter 2001 (Continued)
Selective reporting (reporting bias) Unclear risk Primary outcomes reported as stated at T
= 60. However incomplete reporting for
other time points
Silverman 2002
Methods Design: randomised, double-blind, placebo-controlled study based in the United States
of America (USA). Trial carried out in the EDs of eight hospitals in the USA, but dates
during which this occurred not reported
Final measurement of outcomes performed at 240 minutes and participants followed up
for seven days
Participants Population: 248 participants randomly assigned to control (126) and IVMgSO4 (122)
Inclusion criteria: asthmatic individuals aged 18 to 60 years with an exacerbation (de-
fined as FEV1 < 30%) who were able to stay for 4 hours and consented to being involved
in the trial
Exclusion criteria: co-morbidities such as chronic obstructive pulmonary disease or
other chronic lung disease, pneumonia, temperature > 38.9 ºC, congestive cardiac fail-
ure, coronary artery disease, diabetes mellitus, chronic kidney disease, hypertension,
pregnancy, requiring intubation or unable to do spirometry
Interventions Control group: 50 mL ’like appearing solution’ infused over 10 to 15 minutes and given
at 30 minutes
IV MgSO4 group: 2 g IV MgSO4 in 50 mL 0.9% normal saline infused over 10 to 15
minutes and given at 30 minutes
Co-interventions: All participants received 2.5mg nebulised 0.5% albuterol with 100%
oxygen, 125 mg IV methylprednisolone. Albuterol subsequently given at 30, 60, 120
and 180 minutes
Outcomes FEV1 (at 240 minutes), hospitalisation rate; relapse rate; vital signs; Borg scale; PEF (all
at 30 and 240 minutes)
Notes Funded in part by the Max and Victoria Dreyfus Foundation
Baseline severity of population: life threatening (based on PEF 27% predicted, FEV1
23% predicted)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using a 1:1 ratio ran-
domisation table unique for each centre
Allocation concealment (selection bias) Low risk ’Study pharmacists placed drug or placebo
in identically appearing vials, with only the
study ID on the label’
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Silverman 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind, placebo-controlled’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators blinded (’FEV1 results were
reviewed blindly by the 2 investigators’)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Well-documented attrition rate n = 70
(28%); these ’were retained in the inten-
tion to treat data set.’ However data for in-
dividual arms not given
Selective reporting (reporting bias) Low risk All outcome data given
Singh 2008
Methods Design: randomised, single-blinded, placebo-controlled trial based in Delhi, India. Trial
carried out in a single ED at the Chest Institute
Final measurement of outcomes performed at 180 minutes with no further participant
follow-up
Participants Population: 70 participants of South Asian origin randomly assigned to control (30)
and IV MgSO4 (30)
Inclusion criteria: asthmatic individuals aged 18 to 60 years with a severe exacerbation
(as defined by GINA) and an FEV < 30% predicted on presentation, who were able to
remain in the department for 3 hours
Exclusion criteria: co-morbidities such as chronic obstructive pulmonary disorder
(COPD) or other chronic lung disease, cardiac, renal or hepatic dysfunction, pregnancy
or lactating or requiring intubation or unable to do spirometry
Interventions Control group: 250 mL 0.9% normal saline infused over 20 minutes at 30 minutes
IV MgSO4 group: 2 g IV MgSO4 in 250 mL 0.9% normal saline infused over 20
minutes at 30 minutes
Co-interventions: All participants received 100 mg IV hydrocortisone on arrival (0
minutes). They then received a nebulising solution consisting of: 2.5 mg nebulised
salbutamol, 1.5 mL ipratropium bromide and 2.5 mL normal saline with 100% oxygen
at 0, 20 and 40 minutes
Outcomes Change in FEV1 % predicted, hospitalisation rate; cyanosis; stats; vital signs; Borg score
Notes Trial done as part of an MD dissertation project funded by a grant from University of
Delhi, India
Baseline severity of population: life threatening (based on PEF 22% predicted, FEV1
38% predicted, and high HR 127 bpm)
Risk of bias
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Singh 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using a 1:1 ration ran-
domisation table
Allocation concealment (selection bias) Low risk Random number tables used. ’Individual
random numbers were kept in separate en-
velopes so the concealment could be main-
tained until the patient was included in the
assigned group.’ Placebo described only as
’like appearing placebo’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as a ’single blind study.’ However
further information from the study author
confirmed that participants and assessors
of spirometric and clinical outcomes were
blinded to the treatment given, and the de-
cision to admit was made by chief residents
blinded to type of treatment given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study authors do not specify in the pub-
lished paper who does the spirometry and
clinical examination of the respiratory sys-
tem at each time interval, but further in-
formation from the study authors confirms
that participants and assessors of spiromet-
ric and clinical outcomes were blinded to
the treatment given
Decision to hospitalise or discharge was
made by ED staff blinded to group alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk This is clearly given for both groups (5 in
each group), so it is equal, and total with-
drawal percentage is low at 14%
Selective reporting (reporting bias) Low risk Good reporting of primary outcomes at all
time points for FEV1 and at 120 minutes
for Borg scale and clinical indicators
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Skobeloff 1989
Methods Design: randomised, double-blind, placebo-controlled study based in Philadelphia,
USA. Trial carried out in a single ED between August 1987 and February 1988
Final measurement of outcomes performed at 45 minutes, with the decision to admit at
240 minutes and no reported follow-up of participants
Participants Population: 38 participants randomly assigned to control (19) and IV MgSO4 (19)
Inclusion criteria: asthmatic individuals aged 18 to 70 years with an exacerbation (initial
PEF < 200 L/min) and defined as poor responders to initial treatment
Exclusion criteria: initial PEF > 200 L/min, rectal temperature > 38 ºC, systolic blood
pressure < 120, history of kidney disease, pregnancy, purulent sputum or infiltrate on
chest
Interventions Control group: 50 mL 0.9% normal saline infused over 20 minutes
IV MgSO4 group: 1.2 g IV MgSO4 in 50 mL of 0.9% normal saline infused over 20
minutes
Co-interventions: All participants received nebulised metaproterenol sulphate 0.3 mL
in 3.0 mL of saline or albuterol sulphate 0.5 mL in 2.5 mL of saline at the discretion of
the physician, 125 mg IV methylprednisolone sodium succinate and a loading dose of
theophylline based on participant levels. This was followed by a maintenance infusion
of 0.5 mg/kg/h. 45 to 60 minutes after initial treatment, a second nebulised treatment
was given
Outcomes PEF; hospitalisation rate; heart rate; respiration rate; mean arterial pressure
Notes Baseline severity of population: severe, based on estimates from baseline characteristics
graphs (HR ~ 100 bpm, RR ~ 28 rpm, PEF ~ 150 L/min)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Coded from a randomised list’
Allocation concealment (selection bias) Low risk Placebo/magnesium solutions prepackaged
in identical vials by the pharmacy and
coded from a randomised list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded, randomised, placebo-
controlled trial. Solutions ’prepackaged in
identical vials’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded. ’The decision to admit or
discharge was made by the physician caring
for the patient and not influenced by the
investigator’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals few and well commented on
(2/14 excluded)
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Skobeloff 1989 (Continued)
Selective reporting (reporting bias) High risk All predetermined outcomes reported (ex-
cept deep tendon reflexes, but the relevance
of this is uncertain). However raw data not
provided. Only graphs for some outcomes
Tiffany 1993
Methods Design: randomised, double-blind, placebo-controlled based in Detroit, USA. Trial
carried out in a single ED, the dates of which are not provided
Final measurement of outcomes performed at 260 minutes with no reported follow-up
of participants
Participants Population: 48 participants randomly assigned to control (21) and IVMgSO4 (15), and
one other group that was not relevant to this review (continuous IV MgSO4 infusion n
= 12)
Inclusion criteria: asthmatic individuals aged 18 to 60 years with an exacerbation who
have consented to being involved in the trial
Exclusion criteria: first episode of wheeze, history of chronic lung disease, temperature
> 38.2 ºC, chronic kidney disease, congestive cardiac failure, requiring intubation and
initial PEF > 200 L/min
Interventions Control group: 2 g stat of 0.9% normal saline over 20 minutes followed by a placebo
infusion over 4 hours
IV MgSO4 group: 2 g IV MgSO4 in 0.9% normal saline over 20 minutes followed by
placebo infusion over 4 hours
Co-interventions: All participants received 2.5mgnebulised albuterol 30minutes apart,
125 mg IV methylprednisolone, followed by a third albuterol aerosol treatment and an
aminophylline loading dose and infusion to keep levels at 15 mg/L
Outcomes PEF and FEV1
Notes Baseline severity of population: life threatening (based on PEF L/min 115, and FEV1
0.95 L)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using a ’computerised
random number generation under the con-
trol of the hospital pharmacy’
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Double blind, placebo controlled study.’
’Investigators and patients were blinded to
patient assignment to the study groups’
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Tiffany 1993 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Best of 3 PEF and FEV1 values measured
(objective measurements). ’Clinical deci-
sionmaking (i.e. decision to admit) was left
to attending physicians’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided
Selective reporting (reporting bias) High risk Incomplete and no raw data reported. Re-
sults given only as variances and graphs
ABGs: Arterial blood gases; BP: Blood pressure; BTS: British Thoracic Society; COPD: Chronic obstructive pulmonary disease; ED:
Emergency department; FEV1: Forced expiratory volume in 1 second; GINA: Global Initiative for Asthma; HR: Heart rate; ITT:
Intent-to-treat; IV: Intravenous; Mg: Magnesium; MgSO4: Magnesium sulfate; PaO2: Partial pressure of oxygen in arterial blood;
PEF: Peak expiratory flow; RR: Respiratory rate; VAS: Visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abreu-Gonzalez 2002 Not an ED study. Design did not match inclusion criteria, laboratory study
Brunner 1985 Not an ED study. Design did not match inclusion criteria, laboratory study (’each subject serving as his own
control’)
Cairns 1996a Not an ED study. Design did not match inclusion criteria, laboratory study
Harmanci 1996 Nebulised versus IV MgSO4. Does not appear to have a placebo arm
Hill 1996 Not an ED study. Design did not match inclusion criteria, laboratory study
Liang 1998 No diagnosis of asthma. Child study
Okayama 1987 Not an ED study. Portion of the sample inpatients
Rolla 1988 Not an ED study. Design did not match inclusion criteria and non-emergency patients
Rolla 1994 Not an ED study
Schenk 2001 No diagnosis of asthma
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Characteristics of studies awaiting assessment [ordered by study ID]
Abd El Kader 1997
Methods ’Comparative study’
Participants Patients with bronchial asthma
Interventions Salbutamol, ipratropium bromide and magnesium sulfate
Outcomes Ventilatory, cardiovascular and metabolic responses
Notes Numerous attempts made to locate the paper, but no library holdings found
45Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. IV MgSO4 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hospital admissions 11 1769 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.60, 0.92]
2 Intensive care unit (ICU)
admissions
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 High dependency unit (HDU)
admissions
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 ED treatment duration
(minutes)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Length of hospital stay (days) 3 949 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.33, 0.27]
6 Readmission 2 887 Odds Ratio (M-H, Fixed, 95% CI) 2.30 [0.66, 7.99]
7 Heart rate (bpm) 4 1195 Mean Difference (IV, Fixed, 95% CI) -2.37 [-4.13, -0.61]
8 Respiratory rate (breaths/min) 4 1195 Mean Difference (IV, Fixed, 95% CI) -0.28 [-0.77, 0.20]
9 Systolic blood pressure (mmHg) 4 1264 Mean Difference (IV, Fixed, 95% CI) 0.08 [-1.89, 2.05]
10 FEV1 (% predicted) 4 523 Mean Difference (IV, Fixed, 95% CI) 4.41 [1.75, 7.06]
11 PEF (% predicted) 3 1129 Mean Difference (IV, Fixed, 95% CI) 4.78 [2.14, 7.43]
12 PEF (L/min) 8 1460 Mean Difference (IV, Fixed, 95% CI) 17.40 [8.64, 26.17]
13 Borg Dyspnoea Scale score 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Comparison 2. IV MgSO4 versus placebo (subgroup and sensitivity analyses)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hospital admissions (by severity) 11 1743 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.62, 0.95]
1.1 Moderate 2 791 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.55, 1.04]
1.2 Severe 6 474 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.58, 1.31]
1.3 Life threatening 7 478 Odds Ratio (M-H, Fixed, 95% CI) 0.69 [0.46, 1.03]
2 Hospital admissions (by
co-medications)
11 1769 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.60, 0.92]
2.1 Nebulised ipratropium
bromide
4 1072 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.55, 0.96]
2.2 No nebulised ipratropium
bromide
7 697 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.55, 1.06]
3 Hospital admissions (risk of bias
sensitivity)
8 1437 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.57, 0.91]
4 Hospital admissions
(unpublished sensitivity)
10 1638 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.58, 0.91]
5 PEF % predicted (Goodacre
change score sensitivity)
3 1129 Mean Difference (IV, Fixed, 95% CI) 1.57 [-0.55, 3.69]
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6 PEF L/min (Goodacre change
score sensitivity)
8 1460 Mean Difference (IV, Fixed, 95% CI) 9.44 [2.07, 16.81]
Analysis 1.1. Comparison 1 IV MgSO4 versus placebo, Outcome 1 Hospital admissions.
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 1 Hospital admissions
Study or subgroup Magnesium Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilaceroglu 2001 10/40 17/41 6.3 % 0.47 [ 0.18, 1.21 ]
Bloch 1995 17/67 24/68 8.9 % 0.62 [ 0.30, 1.31 ]
Boonyavorakul 2000 3/17 4/16 1.7 % 0.64 [ 0.12, 3.46 ]
Bradshaw 2007 49/62 52/67 5.3 % 1.09 [ 0.47, 2.52 ]
Goodacre 2013 279/394 278/358 42.6 % 0.70 [ 0.50, 0.97 ]
Green 1992 13/58 11/62 4.1 % 1.34 [ 0.55, 3.29 ]
Matusiewicz 1994 45/64 47/67 6.8 % 1.01 [ 0.48, 2.13 ]
Porter 2001 5/18 5/24 1.6 % 1.46 [ 0.35, 6.08 ]
Silverman 2002 39/122 41/126 13.8 % 0.97 [ 0.57, 1.66 ]
Singh 2008 2/30 9/30 4.2 % 0.17 [ 0.03, 0.85 ]
Skobeloff 1989 7/19 15/19 4.7 % 0.16 [ 0.04, 0.66 ]
Total (95% CI) 891 878 100.0 % 0.75 [ 0.60, 0.92 ]
Total events: 469 (Magnesium), 503 (Placebo)
Heterogeneity: Chi2 = 13.93, df = 10 (P = 0.18); I2 =28%
Test for overall effect: Z = 2.72 (P = 0.0066)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours Magnesium Favours Placebo
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Analysis 1.2. Comparison 1 IV MgSO4 versus placebo, Outcome 2 Intensive care unit (ICU) admissions.
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 2 Intensive care unit (ICU) admissions
Study or subgroup Magnesium Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goodacre 2013 11/394 5/358 2.03 [ 0.70, 5.89 ]
0.01 0.1 1 10 100
Favours Placebo Favours Magnesium
Analysis 1.3. Comparison 1 IV MgSO4 versus placebo, Outcome 3 High dependency unit (HDU) admissions.
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 3 High dependency unit (HDU) admissions
Study or subgroup Magnesium Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goodacre 2013 23/394 20/358 1.05 [ 0.57, 1.94 ]
0.01 0.1 1 10 100
Favours Placebo Favours Magnesium
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Analysis 1.4. Comparison 1 IV MgSO4 versus placebo, Outcome 4 ED treatment duration (minutes).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 4 ED treatment duration (minutes)
Study or subgroup Magnesium Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Green 1992 (1) 45 224 (75) 51 228 (90) -4.00 [ -37.02, 29.02 ]
-100 -50 0 50 100
Favours Magnesium Favours Placebo
(1) Reported only for those who were discharged (i.e. those not counted in hospital admissions)
Analysis 1.5. Comparison 1 IV MgSO4 versus placebo, Outcome 5 Length of hospital stay (days).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 5 Length of hospital stay (days)
Study or subgroup Magnesium Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bilaceroglu 2001 (1) 23 5.7 (2.1) 23 6.1 (1.9) 6.7 % -0.40 [ -1.56, 0.76 ]
Bilaceroglu 2001 (2) 17 7.8 (2.3) 14 9.2 (2.3) 3.4 % -1.40 [ -3.03, 0.23 ]
Goodacre 2013 (3) 394 2.375 (3.129) 358 2.64 (3.5125) 39.6 % -0.26 [ -0.74, 0.21 ]
Green 1992 58 2.4 (1.5) 62 2.1 (0.7) 50.3 % 0.30 [ -0.12, 0.72 ]
Total (95% CI) 492 457 100.0 % -0.03 [ -0.33, 0.27 ]
Heterogeneity: Chi2 = 6.36, df = 3 (P = 0.10); I2 =53%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Magnesium Favours Placebo
49Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(1) moderate
(2) severe
(3) Converted from hours to days
Analysis 1.6. Comparison 1 IV MgSO4 versus placebo, Outcome 6 Readmission.
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 6 Readmission
Study or subgroup Magnesium Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bloch 1995 (1) 3/67 0/68 13.2 % 7.43 [ 0.38, 146.75 ]
Goodacre 2013 (2) 5/394 3/358 86.8 % 1.52 [ 0.36, 6.41 ]
Total (95% CI) 461 426 100.0 % 2.30 [ 0.66, 7.99 ]
Total events: 8 (Magnesium), 3 (Placebo)
Heterogeneity: Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours Magnesium Favours Placebo
(1) within 1 week
(2) within 1 month
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Analysis 1.7. Comparison 1 IV MgSO4 versus placebo, Outcome 7 Heart rate (bpm).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 7 Heart rate (bpm)
Study or subgroup Magnesium Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bloch 1995 (1) 67 102.5 (15.7) 68 99.9 (16.3) 10.6 % 2.60 [ -2.80, 8.00 ]
Goodacre 2013 (2) 394 105.7 (18.1) 358 105.9 (17.5) 47.8 % -0.20 [ -2.75, 2.35 ]
Silverman 2002 (3) 122 96 (15) 126 102 (15) 22.2 % -6.00 [ -9.73, -2.27 ]
Singh 2008 (4) 30 100 (7.43) 30 106.27 (8.34) 19.4 % -6.27 [ -10.27, -2.27 ]
Total (95% CI) 613 582 100.0 % -2.37 [ -4.13, -0.61 ]
Heterogeneity: Chi2 = 13.33, df = 3 (P = 0.004); I2 =78%
Test for overall effect: Z = 2.64 (P = 0.0084)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours Magnesium Favours Placebo
(1) All groups
(2) at 120 mins
(3) at 240 mins
(4) at 120 mins
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Analysis 1.8. Comparison 1 IV MgSO4 versus placebo, Outcome 8 Respiratory rate (breaths/min).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 8 Respiratory rate (breaths/min)
Study or subgroup Magnesium Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bloch 1995 (1) 67 18.9 (3.1) 68 20 (4.1) 15.7 % -1.10 [ -2.32, 0.12 ]
Goodacre 2013 (2) 394 20.6 (5.3) 358 21 (5.4) 40.1 % -0.40 [ -1.17, 0.37 ]
Silverman 2002 (3) 122 20 (4.1) 126 20 (4.1) 22.6 % 0.0 [ -1.02, 1.02 ]
Singh 2008 (4) 30 21.83 (1.55) 30 21.6 (2.46) 21.7 % 0.23 [ -0.81, 1.27 ]
Total (95% CI) 613 582 100.0 % -0.28 [ -0.77, 0.20 ]
Heterogeneity: Chi2 = 3.03, df = 3 (P = 0.39); I2 =1%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 IV MgSO4 versus placebo, Outcome 9 Systolic blood pressure (mmHg).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 9 Systolic blood pressure (mmHg)
Study or subgroup Magnesium Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bloch 1995 (1) 67 122.7 (17.4) 68 126 (15.6) 12.5 % -3.30 [ -8.88, 2.28 ]
Bradshaw 2007 (2) 62 123.5 (33) 67 134.6 (33) 3.0 % -11.10 [ -22.50, 0.30 ]
Goodacre 2013 (3) 394 125.5 (16.5) 358 124.9 (18.5) 61.6 % 0.60 [ -1.92, 3.12 ]
Silverman 2002 (4) 122 123 (18) 126 121 (15) 22.8 % 2.00 [ -2.13, 6.13 ]
Total (95% CI) 645 619 100.0 % 0.08 [ -1.89, 2.05 ]
Heterogeneity: Chi2 = 6.10, df = 3 (P = 0.11); I2 =51%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 IV MgSO4 versus placebo, Outcome 10 FEV1 (% predicted).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 10 FEV1 (% predicted)
Study or subgroup Magnesium Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bilaceroglu 2001 (1) 23 56.8 (19.2313) 23 57.15 (17.6007) 6.2 % -0.35 [ -11.00, 10.30 ]
Bilaceroglu 2001 (2) 17 62.34 (16.245) 17 52.66 (16.6161) 5.8 % 9.68 [ -1.37, 20.73 ]
Bloch 1995 (3) 67 55 (20.4634) 68 56 (20.6155) 14.7 % -1.00 [ -7.93, 5.93 ]
Silverman 2002 (4) 122 48.2 (18.1) 126 43.5 (18.7) 33.6 % 4.70 [ 0.12, 9.28 ]
Singh 2008 (5) 30 62.84 (10.02) 30 56.7 (6.2) 39.7 % 6.14 [ 1.92, 10.36 ]
Total (95% CI) 259 264 100.0 % 4.41 [ 1.75, 7.06 ]
Heterogeneity: Chi2 = 4.64, df = 4 (P = 0.33); I2 =14%
Test for overall effect: Z = 3.25 (P = 0.0011)
Test for subgroup differences: Not applicable
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(2) Severe at 180 mins
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Analysis 1.11. Comparison 1 IV MgSO4 versus placebo, Outcome 11 PEF (% predicted).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 11 PEF (% predicted)
Study or subgroup Magnesium Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bradshaw 2007 (1) 62 65.4 (21.0197) 67 62.8 (21.0197) 13.3 % 2.60 [ -4.66, 9.86 ]
Goodacre 2013 (2) 394 68.6 (23.3) 358 65 (22.7) 64.7 % 3.60 [ 0.31, 6.89 ]
Silverman 2002 (3) 122 62.7 (24.3) 126 53.1 (20.9) 22.0 % 9.60 [ 3.95, 15.25 ]
Total (95% CI) 578 551 100.0 % 4.78 [ 2.14, 7.43 ]
Heterogeneity: Chi2 = 3.64, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 3.54 (P = 0.00040)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 IV MgSO4 versus placebo, Outcome 12 PEF (L/min).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 12 PEF (L/min)
Study or subgroup Magnesium Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bijani 2001 (1) 48 82.6 (40.1836) 33 47.8 (49.9777) 18.3 % 34.80 [ 14.31, 55.29 ]
Goodacre 2013 (2) 394 288.1 (111.2) 358 278.9 (105.5) 32.0 % 9.20 [ -6.29, 24.69 ]
Green 1992 (3) 58 263 (122) 62 278 (104) 4.6 % -15.00 [ -55.69, 25.69 ]
Matusiewicz 1994 (4) 64 279 (112) 67 256 (106.4096) 5.5 % 23.00 [ -14.45, 60.45 ]
Porter 2001 (5) 18 211 (104) 24 252 (108) 1.8 % -41.00 [ -105.62, 23.62 ]
Silverman 2002 (6) 122 272 (144) 126 236 (123) 6.9 % 36.00 [ 2.62, 69.38 ]
Skobeloff 1989 (7) 19 72 (80) 19 8 (80) 3.0 % 64.00 [ 13.13, 114.87 ]
Tiffany 1993 (8) 27 12.4 (27.5396) 21 -1.6 (30.245) 27.9 % 14.00 [ -2.59, 30.59 ]
Total (95% CI) 750 710 100.0 % 17.40 [ 8.64, 26.17 ]
Heterogeneity: Chi2 = 14.08, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 3.89 (P = 0.000099)
Test for subgroup differences: Not applicable
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(1) Mean change at 180 mins
(2) Endpoint at 120 mins
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(7) Mean change at 45 mins. SD estimated from p value.
(8) Mean change at 20 mins. SD calculated from SEM
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Analysis 1.13. Comparison 1 IV MgSO4 versus placebo, Outcome 13 Borg Dyspnoea Scale score.
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 1 IV MgSO4 versus placebo
Outcome: 13 Borg Dyspnoea Scale score
Study or subgroup Magnesium Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bloch 1995 (1) 67 2.8 (1.9) 68 3 (2.2) -0.20 [ -0.89, 0.49 ]
Porter 2001 (2) 18 2.2 (4.65) 24 1.6 (4.65) 0.60 [ -2.24, 3.44 ]
Silverman 2002 (3) 122 1.9 (2.1) 126 2 (2.1) -0.10 [ -0.62, 0.42 ]
Singh 2008 (4) 30 2 (0.83) 30 2.4 (1.35) -0.40 [ -0.97, 0.17 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Magnesium Favours Placebo
(1) Borg Dyspnoea Scale at 120 mins
(2) Borg Dyspnoea Scale at 60 mins; SDs estimated from exact p-value
(3) Borg Dyspnoea Scale at 240 mins
(4) Borg Dyspnoea Scale at 120 mins
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Analysis 2.1. Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 1
Hospital admissions (by severity).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses)
Outcome: 1 Hospital admissions (by severity)
Study or subgroup Magnesium Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Moderate
Bradshaw 2007 16/20 11/19 1.2 % 2.91 [ 0.70, 12.09 ]
Goodacre 2013 279/394 278/358 43.6 % 0.70 [ 0.50, 0.97 ]
Subtotal (95% CI) 414 377 44.8 % 0.76 [ 0.55, 1.04 ]
Total events: 295 (Magnesium), 289 (Placebo)
Heterogeneity: Chi2 = 3.66, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 1.72 (P = 0.085)
2 Severe
Bilaceroglu 2001 (1) 4/23 8/27 3.1 % 0.50 [ 0.13, 1.94 ]
Bloch 1995 10/25 11/49 2.3 % 2.30 [ 0.81, 6.54 ]
Bradshaw 2007 21/30 26/31 3.9 % 0.45 [ 0.13, 1.54 ]
Green 1992 13/58 11/62 4.2 % 1.34 [ 0.55, 3.29 ]
Matusiewicz 1994 45/64 47/67 7.0 % 1.01 [ 0.48, 2.13 ]
Skobeloff 1989 7/19 15/19 4.9 % 0.16 [ 0.04, 0.66 ]
Subtotal (95% CI) 219 255 25.4 % 0.87 [ 0.58, 1.31 ]
Total events: 100 (Magnesium), 118 (Placebo)
Heterogeneity: Chi2 = 11.58, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 0.68 (P = 0.50)
3 Life threatening
Bilaceroglu 2001 (2) 6/17 9/14 3.3 % 0.30 [ 0.07, 1.33 ]
Bloch 1995 7/21 11/14 4.5 % 0.14 [ 0.03, 0.65 ]
Boonyavorakul 2000 3/17 4/16 1.7 % 0.64 [ 0.12, 3.46 ]
Bradshaw 2007 12/12 15/17 0.3 % 4.03 [ 0.18, 91.91 ]
Porter 2001 5/18 5/24 1.6 % 1.46 [ 0.35, 6.08 ]
Silverman 2002 39/122 41/126 14.1 % 0.97 [ 0.57, 1.66 ]
Singh 2008 2/30 9/30 4.3 % 0.17 [ 0.03, 0.85 ]
Subtotal (95% CI) 237 241 29.8 % 0.69 [ 0.46, 1.03 ]
Total events: 74 (Magnesium), 94 (Placebo)
Heterogeneity: Chi2 = 12.12, df = 6 (P = 0.06); I2 =51%
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(. . . Continued)
Study or subgroup Magnesium Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.82 (P = 0.068)
Total (95% CI) 870 873 100.0 % 0.76 [ 0.62, 0.95 ]
Total events: 469 (Magnesium), 501 (Placebo)
Heterogeneity: Chi2 = 27.95, df = 14 (P = 0.01); I2 =50%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Chi2 = 0.63, df = 2 (P = 0.73), I2 =0.0%
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Favours Magnesium Favours Placebo
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(2) Severe
Analysis 2.2. Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 2
Hospital admissions (by co-medications).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses)
Outcome: 2 Hospital admissions (by co-medications)
Study or subgroup Magnesium Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nebulised ipratropium bromide
Bradshaw 2007 (1) 49/62 52/67 5.3 % 1.09 [ 0.47, 2.52 ]
Goodacre 2013 279/394 278/358 42.6 % 0.70 [ 0.50, 0.97 ]
Matusiewicz 1994 45/64 47/67 6.8 % 1.01 [ 0.48, 2.13 ]
Singh 2008 2/30 9/30 4.2 % 0.17 [ 0.03, 0.85 ]
Subtotal (95% CI) 550 522 58.9 % 0.73 [ 0.55, 0.96 ]
Total events: 375 (Magnesium), 386 (Placebo)
Heterogeneity: Chi2 = 4.79, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 2.22 (P = 0.027)
2 No nebulised ipratropium bromide
Bilaceroglu 2001 (2) 10/40 17/41 6.3 % 0.47 [ 0.18, 1.21 ]
Bloch 1995 (3) 17/67 24/68 8.9 % 0.62 [ 0.30, 1.31 ]
0.02 0.1 1 10 50
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(. . . Continued)
Study or subgroup Magnesium Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boonyavorakul 2000 3/17 4/16 1.7 % 0.64 [ 0.12, 3.46 ]
Green 1992 13/58 11/62 4.1 % 1.34 [ 0.55, 3.29 ]
Porter 2001 5/18 5/24 1.6 % 1.46 [ 0.35, 6.08 ]
Silverman 2002 39/122 41/126 13.8 % 0.97 [ 0.57, 1.66 ]
Skobeloff 1989 7/19 15/19 4.7 % 0.16 [ 0.04, 0.66 ]
Subtotal (95% CI) 341 356 41.1 % 0.77 [ 0.55, 1.06 ]
Total events: 94 (Magnesium), 117 (Placebo)
Heterogeneity: Chi2 = 9.09, df = 6 (P = 0.17); I2 =34%
Test for overall effect: Z = 1.58 (P = 0.11)
Total (95% CI) 891 878 100.0 % 0.75 [ 0.60, 0.92 ]
Total events: 469 (Magnesium), 503 (Placebo)
Heterogeneity: Chi2 = 13.93, df = 10 (P = 0.18); I2 =28%
Test for overall effect: Z = 2.72 (P = 0.0066)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 2.3. Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 3
Hospital admissions (risk of bias sensitivity).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses)
Outcome: 3 Hospital admissions (risk of bias sensitivity)
Study or subgroup Magnesium Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bloch 1995 (1) 17/67 24/68 10.8 % 0.62 [ 0.30, 1.31 ]
Boonyavorakul 2000 3/17 4/16 2.1 % 0.64 [ 0.12, 3.46 ]
Bradshaw 2007 (2) 49/62 52/67 6.3 % 1.09 [ 0.47, 2.52 ]
Goodacre 2013 279/394 278/358 51.5 % 0.70 [ 0.50, 0.97 ]
Porter 2001 5/18 5/24 1.9 % 1.46 [ 0.35, 6.08 ]
Silverman 2002 39/122 41/126 16.6 % 0.97 [ 0.57, 1.66 ]
Singh 2008 2/30 9/30 5.1 % 0.17 [ 0.03, 0.85 ]
Skobeloff 1989 7/19 15/19 5.7 % 0.16 [ 0.04, 0.66 ]
Total (95% CI) 729 708 100.0 % 0.72 [ 0.57, 0.91 ]
Total events: 401 (Magnesium), 428 (Placebo)
Heterogeneity: Chi2 = 10.72, df = 7 (P = 0.15); I2 =35%
Test for overall effect: Z = 2.79 (P = 0.0053)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 4
Hospital admissions (unpublished sensitivity).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses)
Outcome: 4 Hospital admissions (unpublished sensitivity)
Study or subgroup Magnesium Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bilaceroglu 2001 (1) 10/40 17/41 6.8 % 0.47 [ 0.18, 1.21 ]
Bloch 1995 (2) 17/67 24/68 9.6 % 0.62 [ 0.30, 1.31 ]
Boonyavorakul 2000 3/17 4/16 1.8 % 0.64 [ 0.12, 3.46 ]
Bradshaw 2007 (3) 49/62 52/67 5.6 % 1.09 [ 0.47, 2.52 ]
Goodacre 2013 279/394 278/358 45.7 % 0.70 [ 0.50, 0.97 ]
Green 1992 13/58 11/62 4.4 % 1.34 [ 0.55, 3.29 ]
Porter 2001 5/18 5/24 1.7 % 1.46 [ 0.35, 6.08 ]
Silverman 2002 39/122 41/126 14.8 % 0.97 [ 0.57, 1.66 ]
Singh 2008 2/30 9/30 4.5 % 0.17 [ 0.03, 0.85 ]
Skobeloff 1989 7/19 15/19 5.1 % 0.16 [ 0.04, 0.66 ]
Total (95% CI) 827 811 100.0 % 0.73 [ 0.58, 0.91 ]
Total events: 424 (Magnesium), 456 (Placebo)
Heterogeneity: Chi2 = 13.30, df = 9 (P = 0.15); I2 =32%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 5 PEF
% predicted (Goodacre change score sensitivity).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses)
Outcome: 5 PEF % predicted (Goodacre change score sensitivity)
Study or subgroup Magnesium Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bradshaw 2007 (1) 62 65.4 (21.0197) 67 62.8 (21.0197) 8.5 % 2.60 [ -4.66, 9.86 ]
Goodacre 2013 (2) 394 14.4 (17.4) 358 14.4 (16.3) 77.4 % 0.0 [ -2.41, 2.41 ]
Silverman 2002 (3) 122 62.7 (24.3) 126 53.1 (20.9) 14.1 % 9.60 [ 3.95, 15.25 ]
Total (95% CI) 578 551 100.0 % 1.57 [ -0.55, 3.69 ]
Heterogeneity: Chi2 = 9.47, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses), Outcome 6 PEF
L/min (Goodacre change score sensitivity).
Review: Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Comparison: 2 IV MgSO4 versus placebo (subgroup and sensitivity analyses)
Outcome: 6 PEF L/min (Goodacre change score sensitivity)
Study or subgroup Magnesium Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bijani 2001 (1) 48 82.6 (40.1836) 33 47.8 (49.9777) 12.9 % 34.80 [ 14.31, 55.29 ]
Goodacre 2013 (2) 394 61 (73.6) 358 62.5 (69.4) 51.9 % -1.50 [ -11.72, 8.72 ]
Green 1992 (3) 58 263 (122) 62 278 (104) 3.3 % -15.00 [ -55.69, 25.69 ]
Matusiewicz 1994 (4) 64 279 (112) 67 256 (106.4096) 3.9 % 23.00 [ -14.45, 60.45 ]
Porter 2001 (5) 18 211 (104) 24 252 (108) 1.3 % -41.00 [ -105.62, 23.62 ]
Silverman 2002 (6) 122 272 (144) 126 236 (123) 4.9 % 36.00 [ 2.62, 69.38 ]
Skobeloff 1989 (7) 19 72 (80) 19 8 (80) 2.1 % 64.00 [ 13.13, 114.87 ]
Tiffany 1993 (8) 27 12.4 (27.5396) 21 -1.6 (30.245) 19.7 % 14.00 [ -2.59, 30.59 ]
Total (95% CI) 750 710 100.0 % 9.44 [ 2.07, 16.81 ]
Heterogeneity: Chi2 = 21.65, df = 7 (P = 0.003); I2 =68%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
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(1) Mean change at 180 mins
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(5) Endpoint at 60 mins
(6) Endpoint at 240 mins
(7) Mean change at 45 mins. SD estimated from p value.
(8) Mean change at 20 mins. SD calculated from SEM
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A D D I T I O N A L T A B L E S
Table 1. Summary of guideline treatment recommendations in acute asthma (adults)
BTS/SIGN GINA NACA NAEPP
Oxygen
√ √ √ √
Inhaled beta2-agonist
√ √ √ √
Inhaled antimuscarinic
√ √ √ √
Sytemic corticosteroids
√ √ √ √
IV beta2-agonist (
√
)
if nebulised form cannot
be used
reliably
x
√
if no response to inhaled
form
x
IV MgSO4
√ √ √
IV or nebulised
√
Heliox x x x
√
IV aminophylline/
theophylline
(
√
)
limited evidence, only
after senior consultation
(
√
)
if inhaled beta2-agonist
unavailable
(
√
)
as an alternative to IV
beta2-agonist
x
BTS/SIGN: British Thoracic Society and Scottish Intercollegiate Guidelines Network joint guideline; GINA: Global Initiative for
Asthma; IV: Intravenous;NACA:National AsthmaCouncil Australia;NAEPP:National AsthmaEducation and Prevention Program;√
: Recommended; x: Not recommended; (
√
): Recommended with conditions.
Table 2. Summary characteristics of included studies
Study ID Country (cen-
tres)
Total N Study design Age range (years) Dose (infusion) Co-medications
Bijani 2001 Iran 81 R, DB, PC 12-85 25 mg/kg (30 min-
utes)
Nebulised SABA, IV
xanthine, IV corti-
costeroid, O2
Bilaceroglu 2001 Turkey 81 R, SB, PC 6-65 1 g or 2 g (unclear) O2 (if PaO2 was < 60
mmHg)
Bloch 1995 USA (2) 149 R, DB, PC 18-65 2 g (20 minutes) Nebulised SABA, IV
corticosteroid
Boonyavorakul
2000
Thailand (1) 34 R, DB, PC 15-65 2 g (unclear) Nebulised SABA, IV
corticosteroid, O2 if
necessary
65Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Summary characteristics of included studies (Continued)
Bradshaw 2007 Scotland (1) 129 R, DB, PC 16+ 1.2 g (15 minutes) Nebulised SABA,
nebulised LAMA, IV
corticosteroid, O2
Del Castillo
Rueda 1991
Spain (1) 16 R, DB, PC ? 1.5 g (15 minutes) Nebulised SABA, IV
corticosteroid
Goodacre 2013 UK (34) 1109 R, DB, PC 16+ 2 g (20 minutes) Nebulised SABA and
LAMA, oral corticos-
teroid, O2
Green 1992 USA (1) 137 ? 18-65 2 g (20 minutes) Nebulised SABA, IV
corticosteroid (others
at physician’s discre-
tion), O2
Matusiewicz
1994
UK (1) 131 R Adults 1.2 g (15 minutes) Nebulised SABA and
LAMA, O2, IV corti-
costeroid (discre-
tionary xanthine)
Porter 2001 USA (1) 42 R, DB, PC 18-55 2 g (unclear) Nebulised SABA, IV
corticosteroid, O2
Silverman 2002 USA (8) 248 R, DB, PC 18-60 2 g (15 minutes) Nebulised SABA, IV
corticosteroid, O2
Singh 2008 India (1) 70 R, SB, PC 18-60 2 g (20 minutes) Nebulised SABA,
nebulised LAMA, IV
corticosteroid, O2
Skobeloff 1989 USA (1) 38 R, DB, PC 18-70 1.2 g (20 minutes) Nebulised SABA, IV
metaproterenol, IV
xanthine
Tiffany 1993 USA (1) 48 R, DB, PC 18-60 2 g (20 minutes) Nebulised SABA, IV
corticosteroid, SABA
aerosol, IV xanthine
DB: Double-blind; IV: Intravenous; LAMA: Long-acting muscarinic antagonist; O2: Oxygen; PaO2: Partial pressure of oxygen in
arterial blood; PC: Placebo-controlled; R: Randomised; SABA: Short-acting beta2-agonist; SB: Single-blind.
Bilaceroglu 2001 included adults and children, but only 10 participants were younger than 18 years of age; mean age was 36 (± 13.4)
years.
66Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Baseline severity criteria
Study ID Inclusion Category
within trial
PEF FEV1 Other Classification*
Bijani 2001 PEF < 200 af-
ter bronchodila-
tor and corticos-
teroids
All participants 31% predicted - RR = 35 rpm Life threatening
Bilaceroglu 2001 PEF increasing <
50% or
FEV1
< 75% predicted
after single
salbutamol
Moderate 57% predicted 43% predicted PaO2 = 69
mmHg
Severe
Severe 32% predicted 32% predicted PaO2 = 64
mmHg
Life threatening
Bloch 1995 FEV1
< 75% predicted
after single
salbutamol
Moderate - 40% predicted - Severe
Severe - 20% predicted - Life threatening
Boonyavorakul
2000
Composite
severity score
All participants - - RR = 33 rpm
HR = 125 bpm
Life threatening
Bradshaw 2007 PEF < 75% pre-
dicted
Moderate 60% predicted
248 L/min
- HR = 102 bpm Moderate
Severe 41% predicted
170 L/min
- HR = 109 bpm Severe
Life threatening 23% predicted
96 L/min
- HR = 116 bpm Life threatening
Del Castillo
Rueda 1991
- All participants - - - Unknown (not in
analysis)
Goodacre 2013 One or more
of the following:
PEF < 50% pre-
dicted; RR > 25,
HR > 110
or cannot com-
plete sen-
tences, but not
life threatening
All participants 52% predicted
433 L/min
- - Moderate
Green 1992 - All participants 143 L/min - RR = 29 rpm
HR = 108 bpm
Severe
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Table 3. Baseline severity criteria (Continued)
Matusiewicz
1994
PEF < 250 L/
min or < 50%
predicted
All participants - - - Severe
Porter 2001 PEF < 100 L/
min or < 25%
predicted
All participants 88.5 L/min - RR = 31 rpm
HR = 110 bpm
Life threatening
Silverman 2002 FEV1 < 30%
predicted
All participants 27% predicted
143 L/min
23% predicted HR = 102 bpm Life threatening
Singh 2008 FEV1 < 30%
predicted
All participants 22% predicted 38% predicted HR = 127 bpm Life threatening
Skobeloff 1989 PEF < 200 L/
min, not dou-
bled after beta-
agonist, IV cor-
ticosteroid, theo-
phylline
All participants ~150 L/min
(from graph)
- HR = ~ 100 bpm
from graph
RR = ~ 28
Severe
Tiffany 1993 PEF
<200L/min, not
doubled after al-
buterol × 2
All participants 115 L/min 0.95 L - Life threatening
bpm: Beats per minute; FEV1: Forced expiratory volume in 1 second; HR: Heart rate; PaO2: Partial pressure of oxygen in arterial
blood; PEF: Peak expiratory flow; rpm: Respirations per minute;RR: Respiration rate..
Classification for the severity subgroup analysis was assigned by an independent clinician and was cross-checked with study authors’
own judgements. Discrepancies were resolved through discussion.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (The Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
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MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 magnesium*
#6 MgSO4
#7 #5 or #6
#8 #4 and #7
#9 (#8) AND (INREGISTER)
[Note: in search line #1, MISC1 refers to the field in which the reference record has been coded for condition, in this case, asthma]
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C O N T R I B U T I O N S O F A U T H O R S
All review authors contributed to all aspects of the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• KK, UK.
National Institute for Health Research (NIHR). Programme grant funding
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We could not carry out the prespecified subgroup analysis based on age, as no studies had a mean participant age above 65 years. For
the severity subgroup analysis, we renamed the categories frommild, moderate and severe to moderate, severe and life threatening to fit
with BTS/SIGN 2012 classifications. For the co-medications subgroup analysis, we changed the labelling from ’maximal and minimal’
to ’with and without ipratropium bromide’ so as not to imply preference of one strategy over the other (definitions remained the same).
We considered a meta-analysis of O2 saturations to be not viable. We added a post-hoc sensitivity analysis using change from baseline
instead of endpoint means from Goodacre 2013, as baseline imbalances were noted in this study.
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